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Summary 
 
Aurora B (Aurkb), one of the three members of the mammalian Aurora kinase family, is the catalytic 
component of the Chromosomal Passenger Complex (CPC), an essential regulator of chromosome 
segregation in mitosis. Despite the numerous studies on Aurora B function in cells, the physiological 
effects of Aurora B deregulation in vivo are unknown. In this work we have analysed conditional genetic 
depletion and overexpression mouse models for Aurkb that allowed us to modulate Aurora B expression in 
murine tissues and cells. Aurora B is indispensable for cell proliferation except during the initial stages of 
embryonic development in which it is substituted by Aurora C (Aurkc). Its widespread elimination in adult 
tissues led to an ageing phenotype characterized by proliferative defects and aneuploidy. The observed 
mitotic arrest in tissues was a consequence of less regenerative capacity of adult stem cells. This was 
accompanied by a stress response characterized by the induction of p53 and p21Cip1. On the other hand, 
Aurkb is overexpressed in human tumours although whether this kinase may function as an oncogene in 
vivo is not established. Here, we take advantage of a new mouse model in which the expression of the 
endogenous Aurkb locus can be induced in vitro and in vivo. Overexpression of Aurora B in cultured cells 
induced defective chromosome segregation and aneuploidy. Long-term overexpression of Aurora B in vivo 
resulted in aneuploidy and the development of multiple spontaneous tumours in adult mice including high 
incidence of lymphomas. In line with previous reports linking Aurora B with p53 activity, overexpression of 
Aurora B resulted in reduced DNA damage response and decreased levels of the p53 target p21Cip1 in 
vitro and in vivo, in concordance with an inverse correlation between Aurora B and p21Cip1 expression in 
human leukaemias. Thus, overexpression of Aurora B may contribute to tumour formation not only by 
inducing chromosomal instability but also suppressing the function of the cell cycle inhibitor p21Cip1. In 
addition, overexpression of Aurora B in vivo resulted in the deposit of white adipose tissue (WAT) inside 
the Brown adipose tissue (BAT), liver steatosis and in adipose hyperplasia, which suggests a role for 
Aurora B outside mitosis. Finally, since Aurora C is the kinase that drives mitosis in early zygotes, we have 
analysed its role in stemness potential. Our data suggest that Aurora C is induced during the 
reprogramming process and that its upregulation results in enhanced number of stem cells colonies during 
reprogramming accompanied by deregulation of specific epigenetic marks. These data suggest specific 
functions for Aurora C in the pluripotent condition. 
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Resumen 
 
La quinasa Aurora B (Aurkb), uno de los tres miembros de la familia de quinasas Aurora, es el 
componente catalítico del complejo pasajero de los cromosomas (CPC), un regulador esencial de la 
segregación cromosómica durante el proceso de mitosis. Aunque su función celular se ha estudiado en 
detalle, los efectos fisiológicos de su desregulación in vivo se desconocen. En este trabajo hemos 
analizado dos modelos animales para Aurora B, uno de elimación y otro de sobre-expresión que nos han 
permitido modular la expresión de Aurora B en células y tejidos de ratón. Aurora B es indispensable para 
una adecuada proliferación celular excepto durante las primeros estadíos del desarrollo embrionario en 
los que es sustituida por Aurora C. Su eliminación en tejidos adultos lleva a un fenotipo de envejecimiento 
prematuro, caracterizado por defectos en proliferación y aneuploidía. El arresto mitótico observado en los 
tejidos es consecuencia de una menor capacidad regenerativa de las células madre adultas. Además 
observamos una respuesta al estrés caracterizada por una inducción de p53 y p21Cip1. Por otra parte, 
Aurora B está sobre-expresada en tumores humanos aunque no está establecido si puede funcionar 
como un oncogen. Gracias a la generación de un nuevo modelo animal inducimos la expresión del gen 
endógeno de Aurora B in vitro e in vivo. La sobre-expresión de Aurora B en células induce defectos en la 
segregación cromosómica y aneuploidía y a largo plazo en ratones adultos provoca aneuploidia y 
múltiples tumores, predominantetmente linfomas. En consonancia con resultados anteriores que 
correlacionan Aurora B con la actividad de p53, la sobre-expresión de Aurora B provoca una menor 
respuesta al daño al DNA y una disminución en los niveles de la diana de p53, el inhibidor del ciclo celular 
p21Cip1, in vitro e in vivo. Datos que están en consonancia con la correlación inversa en cuanto a la 
expresión de Aurora B y p21Cip1 en leucemias humanas. Además los ratones que sobre-expresan Aurora 
B presentan tejido adiposo blanco en el tejido adiposo marrón, esteatosis en hígado e hiperplasia de 
adipocitos, lo que indica un posible papel de Aurora B fuera de mitosis. Finalmente, debido a que Aurora 
C es la quinasa encargada de dirigir la mitosis durante los primeros estadíos embrionarios decidimos 
analizar el papel de Aurora C en la generación de la condición pluripotente. Observamos su activación 
durante la reprogramación celular además de un aumento en la eficiencia de formación de colonias y 
desregulación de marcas epigenéticas cuando sobre-expresamos Aurora C, sugiriendo funciones 
específicas de esta quinasa en el mantenimiento del potencial pluripotente.     
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7  
Introduction  
1. The mammalian Cell Division Cycle 
“Omnis cellula e cellula”, an important dogma in cell biology, was born when Rudolf Virchow in 1858 
established that every cell must derive from a pre-existing cell. And indeed cell division is the only way for 
life to expand and, unfortunately, when uncontrolled also the way for cancer. Cell division cycle describes 
a series of events that ensures faithfully the transition of the genetic information from one cell generation 
to the next. The majority of mammalian adult cells are in a quiescent state called G0, and only when they 
are exposed to specific mitogenic stimuli or signaling cells enter the cell cycle. In eukaryotic cells, the cell 
cycle was first described as two distinct phases: interphase and mitosis. Interphase was later on divided 
into three phases, S-phase standing for synthesis of DNA, surrounded by two Gap-phases G1 (gap1) and 
G2 (gap2). The stage for the synthesis of DNA in which the cell prepares and grows is G1, next during S-
phase the cell replicates its genetic material and in G2 the cell prepares for its division. During mitosis (M 
phase) the cell segregates its DNA into two daughter cells (Figure 1). 
 
 
 
Figure 1. Cell cycle phases. Quiescent cells in G0 decide to 
cycle and enter into G1 to prepare for the DNA synthesis in S 
phase. Once the genome is duplicated cells prepare to divide in 
G2. Finally, chromosome segregation takes place in M phase and 
cell divides (Adapted from BD Biosciences resources). 
 
 
 
 
 
Mitosis, described by Walter Flemming in 1882, is the nuclear division process in which the 
previously duplicated genome is reorganized into compact chromosomes, each made up of two sister 
chromatids that are equally segregated into two daughter cells. It is the most spectacular and 
sophisticated part of the cell cycle. In less than an hour the mother cell organizes a complex machinery 
aiming to have each daughter cell inherit a complete set of chromosomes, a centrosome (the main 
microtubule-organizing centre of animal cells) the cytoplasm and organelles. Mitosis is characterized by 
five different phases: prophase (P), prometaphase (PM), metaphase (M), anaphase (A) and telophase (T) 
(Figure 2).  
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Figure 2. The phases of Mitosis. Interphasic chromatin is condensed and kinetochores assemble in prophase. In prometaphase, 
nuclear envelope breakdown and kinetochores bind to microtubules. Chromosomes are bioriented and aligned during metaphase 
in the spindle midzone, forming a metaphase plate. In anaphase, sister chromatids are pulled apart. At telophase, chromatin 
decondenses and the nuclear envelope is reformed. During cytokinesis, the cortex constricts under the action of the actomyosin 
ring (Adapted from (Salaun et al., 2008). 
 
During prophase, interphasic chromatin starts to condense into chromosomes that move to the 
poles of the cell where the spindle structure will be formed. Then, prometaphase begins with the nuclear 
envelope breakdown and the mitotic spindle formation; a dynamic bipolar array of microtubules. The 
spindle microtubules are then captured by the chromosome’s kinetochores, a proteinaceous structure 
located on the centromeres of chromosomes. Microtubules from opposite poles interact with 
chromosomes and make them become bioriented and congressed, reaching the equator of the spindle 
thus forming the “metaphase plate”. Once all the chromosomes are properly bioriented, a loss of sister-
chromatin cohesion triggers the anaphase step. Early in anaphase, chromosomes lose their cohesion and 
each chromatid moves apart towards one spindle pole. At late anaphase, the spindle is elongated and 
separates further the two set of chromatids. In telophase, the two daughter chromosomes reach the 
spindle poles, chromatin decondenses and the nuclear envelope is reformed around the two daughter 
chromosomes. Then, the cytoplasm division, also called cytokinesis and whose regulation is precisely 
linked to mitosis, occurs. A contractile ring is formed at the cortex of the cell giving rise to the midbody that 
marks the abscission site. This is the final step of cell division that physically separates the two daughter 
cells from each other (Glotzer, 2005; Guertin et al., 2002) (Figure 2). 
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2. Cell Cycle Checkpoints 
 
Dividing cells must wait until their DNA is completely duplicated before they can segregate the replicas. 
They must also delay the next round of DNA replication until the copies are safely deposited in two newly 
born daughter cells. The order and completion of these events are crucial; otherwise, chromosomes 
become unstable, and processes such as cancer may result. To ensure their proper progression through 
the cell cycle, cells have developed a series of checkpoints that prevent them from entering into a new 
phase until they have successfully completed the previous one (Malumbres and Barbacid, 2001). 
A quiescent cell has first to decide whether to cycle or not. The cell has to balance the mitogenic 
and anti-mitogenic signals to decide whether to enter or not into the cell cycle (Pardee, 1974). Once cells 
reach the restriction point they are committed to enter mitosis and replicate its genome. This decision is 
crucial since cycling under improper conditions may cooperate with tumour progression. Indeed, cancer 
cells are characterized by alterations in their signal transduction pathways leading to overproliferation 
(Hanahan and Weinberg, 2000). 
Moreover, the genome must remain stable to prevent uncorrected processes such as malignant 
cell transformation. Mammalian cells display DNA damage checkpoints in order to sense any kind of 
damage to the DNA and transduce the signal to activate the p53 and retinoblastoma (pRb) tumour 
suppressor pathways. These pathways allow the cell with time to repair its DNA avoiding its entrance into 
mitosis until the damage has been repaired (Bartek et al., 2004); (Kastan and Bartek, 2004) (Lukas et al., 
2006). The DNA damage checkpoint can arrest cell cycle progression during G1/S, S phase or at G2/M 
stage. 
2.1. The Spindle Assembly Checkpoint 
 
Cells have developed a surveillance mechanism to monitor kinetochore-microtubule attachment called the 
spindle assembly checkpoint (SAC), which delays the onset of anaphase until all chromosomes are 
properly bioriented. If a single kinetochore is not attached to the spindle, the spindle checkpoint is 
activated, thus maintaining the fidelity of chromosome segregation (Musacchio and Hardwick, 2002). 
(Figure 3). 
The SAC is an important safeguard mechanism that ensures faithful chromosome segregation in 
eukaryotic cells. The effector of the SAC is known as the mitotic checkpoint complex (MCC), it is located 
at unattached kinetochores and is composed by the mitotic arrest deficient 2 protein (Mad2), mitotic 
checkpoint serine/threonine-protein kinase BUB1 beta (BubR1) and the mitotic checkpoint protein Bub3 
(Sudakin et al., 2001) 
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Figure 3. The Spindle Assembly Checkpoint. During PM to A, kinetochores catalyze the formation of the MCC, composed of 
Mad2, BubR1, Bub3 and Cdc20, leading to the inhibition of the APC/C. Once all the chromosomes are aligned at the metaphase 
plate, MCC allows Cdc20 to activate the APC/C leading to the degradation of cyclin B1 and securin. Securin degradation liberates 
separase which cleaves the cohesion ring structure allowing sister chromatids to separate , while cyclin B1 degradation allows 
Cdk1 inactivation and exit from mitosis (Peters, 2006). 
 
The MCC inhibits the cell division cycle 20 (Cdc20), a protein that activates the ubiquitin ligase 
anaphase-promoting complex/cyclosome (APC/C). Once the chromosomes are properly bioriented, the 
SAC is satisfied and Cdc20 is free to activate the APC/C-polyubiquitinilation of two substrates, cyclin B1 
and securin. Securin is an inhibitor of a protease known as separase, which cleaves the cohesion complex 
that holds sister chromatids together, a process that is necessary to execute anaphase. Cyclin B1 
proteolysis is required to inactivate Cdk1 and thus exit mitosis (Figure 3).  
3. Control of mitosis and cytokinesis by phosphorylation 
Cell cycle progression requires the controlled activation of different families of serine/threonine kinases 
that by phosphorylation regulate different cellular processes to ensure a proper segregation of 
chromosomes. The cyclin-dependent kinases (Cdks) are heterodimeric proteins composed of a catalytic 
subunit (Cdk) and a regulatory subunit, known as cyclin. There are twenty Cdks that must associate to a 
cyclin to become active kinases. Cyclins expression and degradation impose waves of kinase activation 
and inactivation that control cell cycle commitment, DNA synthesis and mitosis onset (Malumbres and 
Barbacid, 2005). To enter into mitosis, Cdk1 must be activated by A-type cyclins during prophase and by 
cyclin-B after the nuclear envelope breakdown (Draetta et al., 1989; Karaiskou et al., 2001). The complex 
formed by Cdk1/cyclin B which is known as the Maturation Promoting Factor (MPF) is consider as the 
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master regulator at the onset of mitosis due to its role in key processes such as nuclear envelope 
breakdown, centrosome separation and chromosome condensation between others. This complex must  
be inactivated to exit from mitosis upon SAC inactivation and Cyclin B degradation by the APC/C 
(Malumbres, 2011). 
The DNA damage kinases have also a role in mitosis. The main DNA damage kinases are Atm 
(Ataxia-Telangiectasia Mutated) and Atr (Atm and Rad3 related) and the checkpoint kinases Chk1 and 
Chk2. When they are activated, they regulate kinases such as Wee1 and Myt1, which inactivate Cdks or 
phosphatases such as Cdc25 family, which activate Cdks by removing their previous phosphorylations 
(Malumbres, 2011). 
Mitotic kinases are the kinases of the Polo, Nek and Aurora families that regulate centrosome 
cycle, spindle functioning and chromosome segregation during mitosis. Polo-like (Plk) family is 
characterized by the presence of a specific domain, known as the polo box (PBD), involved in protein-
protein interactions and is formed by five members in mammals, Plk1 being the best characterized. Plk1 
activates mitotic entry by phosphorylating Cdk-cyclin B. Plk1 is also implicated in centrosome maturation, 
cohesion release in prophase and cytokinesis initiation (Barr et al., 2004). Plk2 and Plk3 are mitogen 
activated kinases with tumour suppressor functions (Eckerdt et al., 2005; Kleylein-Sohn et al., 2007). Plk1 
to Plk4 are involved in centrosome biology as well as the regulation of mitosis, cytokinesis, and cell cycle 
checkpoints in response to genotoxic stress, whereas Plk5 is a new member of the vertebrate family, that 
has evolved as a kinase-deficient PBD-containing protein with nervous system-specific functions and 
tumour suppressor activity in brain cancer (de Cárcer et al., 2011).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Overview of mammalian cell cycle kinases. A typical cell is represented that grows in size after entering the cell 
cycle. During the S phase the genome (blue) is duplicated and chromosomes condensate during mitosis to be equally segregated 
between the two daughter cells. Microtubules are represented as red lines and centrioles as small cylinders (Modified from 
(Malumbres, 2011). 
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The NIMA-related kinase (Nek) family consists on eleven members being Nek2 the best known (O'Connell 
et al., 2003). Nek2 is known to be a core component of the human centrosome and crucial for cytokinesis 
(Fry, 2002). Within the group of mitotic kinases, the Aurora kinase family includes key mitotic regulators 
that will be described in detail in the fifth section. 
There are also crucial kinases implicated in SAC regulation such as BubR1, the Mitotic 
checkpoint serine/threonine-protein kinase Bub1 (budding uninhibited by benzimidazoles 1) and 
Monopolar spindle 1 (Mps1). Their function is also tightly linked to their localizations during mitotic 
progression, “being at the right place at the right time” (Figure 4). BubR1 associates and directly 
phosphorylates Cdc20, similar to Mad2 (Skoufias et al., 2001; Tang et al., 2001). BubR1 and Mad2 
enhance each other's ability to bind to Cdc20 and they function synergistically in inhibiting APC, thus 
leading to a complete arrest of mitotic progression (Fang, 2002).  
 
4. Chromosomal instability and Cancer  
 
4.1. Chromosomal Instability 
 
Chromosome Instability (CIN) is defined as the condition in which cells are unable to properly segregate 
whole chromosomes or are prone to their structural rearrangements. The immediate consequence of CIN 
is aneuploidy, a condition in which the number of chromosomes in a cell is not an exact multiple of the 
haploid set. Notwithstanding, alterations in DNA repair pathways or in the maintenance of telomeres have 
been suggested as CIN inducers (Thompson & Compton, 2010). A significant number of studies have 
pointed to abnormalities in the regulation of mitosis as a contributing cause of chromosomal instability 
(Albertson et al., 2003; Holland and Cleveland, 2009; Pérez de Castro et al., 2007; Schvartzman et al., 
2010). Since correct chromosome segregation is essential to maintain an intact genome, errors in this 
process can lead to mitotic aberrations. Thus, defects in mitotic checkpoints (Cahill et al., 1998), the 
anchoring of chromosomes to the mitotic spindle (Bakhoum et al., 2009a; Bakhoum et al., 2009b), 
chromosome cohesion (Zhang et al., 2008b) or the number of centrosomes or cytokinesis (Silkworth and 
Cimini, 2012), might cause chromosome mis-segregation. This process can be produced in the form of 
merotelically attached lagging chromosomes, which lag behind at the spindle equator while all the other 
chromosomes move towards the spindle poles (Cimini et al., 2001). This can result in an aberrant cell 
division leading to aneuploid daughter cells (Figure 5). 
CIN is a hallmark of many tumour types. Indeed it has been proposed as a driving force in tumour 
initiation (Schvartzman et al., 2010; Shih et al., 2001), as it will be latter explained. 
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4.2. Aneuploidy 
 
Errors in chromosome segregation can result in daughter cells with an incorrect number of chromosomes 
that is different from the haploid set, which is called aneuploidy. It is important to note that aneuploidy and 
CIN are not equivalent. Aneuploidy defines the state of having an abnormal chromosome number, while 
CIN refers to an elevated rate of chromosome gain or loss. Most human cancers contain aneuploid cells 
(Albertson et al., 2003) (Pérez de Castro et al., 2007) and since this feature was first postulated by Boveri 
a century ago (Boveri, 1902), many efforts have been done to know how it contributes to tumourigenesis. 
Both are common characteristics in tumour development (Schvartzman et al., 2010), however, CIN can 
generate aneuplodies whereas not all aneuploid cells present CIN and are capable of maintaining an 
invariable karyotype for a long time.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Pathways that lead to aneuploidy .There are different pathways by which cells may gain or lose chromosomes during 
mitosis. (a) Mitotic checkpoint defects. A weakend mitotic checkpoint might allow cells to enter anaphase in the presence of 
unattached or misaligned chromosomes. (b) Cohesion defects. Chromosomes can be missegregated when sister chromatid 
cohesion is lost prematurely or persists during anaphase. (c) Merotelic attachment that occurs when one kinetochore attach to 
microtubules from both poles of the spindle. If these attachments persist then lagging chromatids are formed that can be 
misegregated or excluded from daughter cells during cytokinesis. (d) Multipolar divisions are produced when cell possess more 
than two centrosomes thus forming multiple spindle poles during mitosis.If the defect is not corrected then multipolar division 
occurs resulting in aneuploid cells Adapted from (Holland and Cleveland, 2009). 
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Whether aneuploidy alone is a sufficient driving cause during tumourigenesis or rather a mere 
consequence has been a matter of scientific debate. This clue has remained untested due to the difficulty 
of selectively generating aneuploidy. It has been described that when depleting the centromere-linked 
motor protein CENP-E, an increased rate of aneuploidy does drive an elevated level of spontaneous 
lymphomas and lung tumours in aged animals (Weaver et al., 2007). However, reduction of CENP-E 
actually inhibits tumourigenesis in the presence of additional genetic damage and in examples of 
chemically or genetically induced tumour formation, an increased rate of aneuploidy is a more effective 
inhibitor than initiator of tumourigenesis (Weaver et al., 2007). 
It was postulated that aneuploidy drives tumourigenesis by a mechanism in which oncogenes are 
gained or tumour suppressor genes are lost (Lengauer et al., 1998). More recently it has been proposed 
that aneuploidy also produces metabolic and energetic alterations that induce cellular imbalances and 
proteotoxic stress (Torres EM et al., 2007). 
At the moment, it is still not known whether CIN promotes or inhibits tumourigenesis or if it 
contributes to both processes. When excessive DNA damage occurs, CIN probably has a tumour 
suppressive effect whereas when CIN is moderate alone or in conjunction with other tumoural signals it 
can contribute to the tumoural process (Figure 6) (Weaver and Cleveland, 2009).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.The consequences of CIN. Divisions in a hypothetical cell with three chromosomes are represented. (a) Normal cells 
do not exhibit CIN and produce genetically identical progeny. (b) Animals heterozygous for the mitotic checkpoint components 
Mad1, Mad2, or CENP-E missegregate one or a few chromosomes per division (low CIN) and exhibit a modest tumour 
phenotype. Approximately 20–25% of these animals develop late onset spontaneous tumours. (c) Coupling a low rate of CIN with 
another tumour-promoting activity, results in a higher rate of tumour formation with a shorter latency. (d) High rates of CIN lead to 
massive chromosome missegregation and cell death. Adapted from (Weaver and Cleveland, 2009).  
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4.3. Mouse models of aneuploidy 
 
Several animal models with mutations in genes implicated in the mitotic machinery develop tumours, 
suggesting a causal relationship between mitotic defects and tumour development (Schvartzman et al., 
2010). The main mechanisms behind this state are defects in mitotic checkpoint signalling, in genes 
implicated in chromosome cohesion, attachment (mainly merotely) or defects on spindle formation 
(Holland and Cleveland, 2009).  
Reduced expression of mitotic components, as well as its overactivation, is associated with an 
increase of spontaneous cancer and in some cases with aneuploidy. Several mouse models of mitotic 
regulators have been generated with this purpose, including mitotic checkpoint proteins such as Mad2 or 
BubR1, mitotic kinases like AurkA or Plk1, APC proteins such as Cdc20 or Cdh1 or motor proteins like 
CenpE or Hec1. For instance, Bub1 hypomorphic mice develop lymphomas, lung and liver tumours with 
high incidence (Jeganathan et al., 2007); whereas heterozygous animals for Mad2 develop benign lung 
tumours with long latencies (Dobles et al., 2000). Likewise, CenpE heterozygous animals evolve benign 
lung tumours but also splenic lymphomas (Weaver et al., 2007) and heterozygous BubR1 mice are prone 
to develop colon adenocarcinomas when carcinogenesis is induced (Dai et al., 2004) or in a background 
of an APC (min) mutation (Rao et al., 2005). 
However, whereas mutations that inactivate mitotic genes are rarely observed in human cancers, 
overactivation of these genes is a much more frequent event than their loss or partial loss of function. In 
this way, Mad2, Hec1 or Bub1 overexpression that correlate with tumour grade and prognosis in a variety 
of human tumours (Tanaka et al.; 2008; Garber et al., 2001; Shigeishi et al., 2001) is known to drive 
aneuploidy and to initiate tumourigenesis in inducible murine models (Sotillo et al.; 2008; Díaz-Rodríguez 
et al.; 2008; Ricke et al.; 2011). These overexpression models result in aneuploidies in vitro and in an 
increase of tumour incidence in vivo. Although there is no direct correlation between the level of 
aneuploidy and the incidence of spontaneous tumours (Jenagathan et al.; 2007; Baker et al.; 2006; 
Jenagathan et al.; 2005), aneuploidy can increase the risk of neoplastic transformation.  
5. The Aurora family of protein kinases 
Early work in Drosophila led to the identification of Aurora mutants, which carry a loss-of function mutation 
in a serine/threonine kinase essential for centrosome separation and the formation of bipolar spindles 
(Glover et al., 1995). The Aurora family of Ser/Thr kinases (Aurk) is a highly conserved family of cell cycle 
regulators which are key to ensure a proper segregation of chromosomes during mitosis. A single Aurora 
protein exists in budding (Ipl1) or fission (Ark1) yeast, whereas two family members, Aurora A and Aurora 
B, are present in worms, flies and frogs. In mammals, there are three different members of this family 
known as Aurora A, B and C.  
Introduction                
 
 
16  
5.1. Structure, function, localization and regulation 
 
The three kinases present high structural similarity, 77% between Aurora A and B and 85% between 
Aurora B and C (Carmena and Earnshaw, 2003). Indeed, Aurora B and C are close paralogs that probably 
arose from a cold-blooded vertebrate common ancestor (Brown et al., 2004).Although they are highly 
conserved at the protein level, the three kinases have very distinct functions and localization patterns 
during cell division (Nigg, 2001) (Figure 7), though all three kinases are involved in the control of many 
processes required for mitosis. Aurora A and B are ubiquitously expressed in mammals, however, much 
less is known about Aurora C, whose expression is largely limited to germ cells (Carmena and Earnshaw, 
2003). The kinase activity of the Aurora family is regulated by phosphorylation and dephosphorylation 
processes and their protein levels are controlled by ubiquitin mediated proteolysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Mammalian Aurora kinases localization. Subcellular localization of Aurora-A (red) and Aurora-B (green) relative to 
the chromosomes (blue) during (a) prophase, (b) prometaphase, (c) metaphase, (d) anaphase and (e) telophase. During 
prophase, Aurora-A localizes to the centrosomes, whereas in later stages of mitosis it is at the spindle poles (c, d and e) and also 
extends up the spindle. During prometaphase and metaphase (a and b), Aurora-B localizes to the centromeres. After anaphase 
(d), however, Aurora-B localizes to the spindle midzone, and finally accumulates at the midbody during telophase (e). 
Chromosomes in blue, Aurora A in red and Aurora B in green. Modified from (Carmena and Earnshaw, 2003; Keen and Taylor, 
2004). 
 
5.1.1. Aurora A: centrosomes and spindle 
 
Aurora A, the orthologue to the original Drosophila kinase localizes on duplicated centrosomes from the 
end of S-phase to the beginning of G1 phase. Aurora A is required for building a bipolar spindle and for 
regulating centrosome maturation and separation (by recruitment of proteins involved in microtubule 
nucleation). It is also involved in mitotic entry and microtubule dynamics (the kinase phosphorylates motor 
proteins and proteins for astral microtubule nucleation) (Giet et al., 2005) (Barr and Gergely, 2007). Aurora 
A is implicated in these processes through interaction with its effectors including Tpx2, Eg5, Ndel1 and 
Lats to name a few. 
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Aurora A activation depends on its autophosphorylation in the T-loop (Cheeseman et al., 2002) 
whereas it is negatively regulated by the phosphatase PP1 (Francisco et al., 1994). But its main regulator 
is Tpx2 (Kufer et al., 2002). When Tpx2 binds to Aurora A it induces a conformational change in a way that 
the phosphorylated T-loop adopts a compact position providing the platform for substrate binding and 
hiding the phosphoryl group from the attack by PP1(Bayliss et al., 2003). Moreover, Tpx2 promotes Aurora 
A autophosphorylation, thus indirectly regulating Aurora A activity (Eyers et al., 2003). It has also been 
demonstrated that Ajuba and Pak 1 regulate Aurora A activity (Hirota et al., 2003). During mitotic exit, 
Aurora A is degraded by the proteasome in an APC/C-Cdh1 manner (Castro et al., 2002) in a tightly 
regulated way since D-box degradation motif is only functional when A-box is non-phosphorylated 
(Littlepage and Ruderman, 2002). 
 
5.1.2. Aurora B: the catalytic member of chromosomal passenger complex (CPC) 
 
Aurora B, was first identified in S. cerevisiae (as Ipl1) in a screen for mutants that display an increase in 
ploidy (Chan and Botstein, 1993). Aurora B is the catalytic component of a multiprotein complex, named 
the Chromosomal Passenger Complex (CPC), which comprises other three non-enzymatic subunits: the 
scaffolding protein Incenp, Survivin and Borealin/DasraB (Ruchaud et al., 2007), that controls the 
targeting, activity and stability of Aurora B, and play key functions during mitosis including chromosome 
interactions with microtubules, chromatid cohesion, spindle stability and cytokinesis (reviewed in 
(Carmena et al., 2009) (Figure 8).  
 
 
 
 
 
 
 
 
 
Figure 8. Schematic representation of the Chromosomal Passenger Complex (CPC). Schematic representation of direct 
interactions between CPC proteins and phosphorylations of Aurora-B within the CPC. Survivin and Borealin interact with the NH2 
terminus of INCENP, whereas Aurora-B binds the COOH-terminal IN-box in INCENP. Mapped Aurora-B phosphorylation sites are 
indicated (Vader et al., 2006). 
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The CPC is highly dynamic, it is firstly located on chromosome arms and in prometaphase and 
metaphase it is concentrated in inner centromeres. In anaphase, it relocates to the central spindle and 
during telophase and cytokinesis it relocates to the midbody. The CPC is one of the upstream regulators 
of kinetochore-microtubule attachment by recruiting to the kinetochore a growing number of proteins 
including: inner centromeric proteins (Sgo1, Sgo2, MCAK), microtubule-kinetochore regulators (Ndc80, 
CenpE, Plk1) or SAC proteins such as Mad2, BubR1 or Mps1 (Kelly and Funabiki, 2009). Some of these 
molecules are Aurora B substrates such as the mitotic centromere associated kinesin (MCAK) and the 
kinesin family member Kif2b (Nezi and Musacchio, 2009)., or Hec1/Ndc80, component of the KMN 
network (named for the Knl1 , the Mis12 and the Ndc80 complex; is part of the protein architecture within 
kinetochores that links centromeric DNA to the plus ends of spindle microtubules (Kline-Smith et al., 
2004). By their recruitment to outer kinetochores, Aurora B promotes the correction of microtubule mis-
attachments (Cheeseman and Desai, 2008; Santaguida and Musacchio, 2009; Maresca and Salmon, 
2010). 
It has been recently described that Aurora B substrate phosphorylation depends on the distance 
of Aurora B to the substrate on the inner centromere. So that when Aurora B is recruited to the 
kinetochores it prevents inappropriate attachments and activates the SAC (Liu et al., 2009), thus 
promoting chromosome bi-orientation by correcting mis-attachments. In response to a lack of tension in 
budding yeast Aurora kinase, Ipl1 is required for SAC function (Biggins and Murray, 2001), although in 
mammals its role in SAC functioning is on debate (Ditchfield et al., 2003; Hauf et al., 2003; Santaguida et 
al., 2011). Likely, mammalian Aurora B is not essential for the SAC but it might partially contribute as a 
separate arm (Morrow et al., 2005) to the SAC response by recruiting  BubR1 to kinetochores (Fernández-
Miranda et al., 2011).  This was first proposed as a result of studies in budding yeast suggesting that 
Aurora activity was required for kinetochores to release bound microtubules (Tanaka et al., 2002). Aurora 
B in the centromere would continually promote disruption of kinetochore–microtubule attachments until the 
bi-oriented chromosome came under tension.  
Aurora B is specifically required for the correction, before anaphase, of merotelic attachment (a 
single kinetochore is attached to microtubules emanating from both spindle poles), an error of kinetochore-
microtubule attachment that occurs frequently during the early stages of mitosis but is not detected by the 
spindle assembly checkpoint (SAC) (Gregan et al., 2011; Lampson and Cheeseman, 2011). These 
attachments can result in improper chromosome segregation and are a significant source of aneuploidy 
(Cimini et al., 2001; Cimini et al., 2002). This correction is likely possible by the recruitment of MCAK that 
is capable of depolymerizing improper attach microtubules (Andrews et al., 2004) (Lan et al., 2004) 
(Zhang et al., 2007) together with additional proteins, thus allowing reorientation of the kinetochore 
towards the correct spindle pole (Figure 9). 
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Figure 9. Aurora B promotes chromosome biorentation on 
the mitotic spindle.The first attachement of chromosomes to 
spindle microtubules is monotelic (one kinetochore bound and 
one kinetochore). When both kinetochores are attached to the 
same spindle pole, syntelic attachment is formed or it can occur 
that a single kinetochore is bound to microtubules from both 
poles thus generating merotelic attamentes. Aurora B, in the 
inner centromere promotes the formation of monotelic 
attachments. Eventually, chromosomes become attached to 
both spindle poles (amphitelic attachment). Modified from 
(Montembault and Pringent, 2005). 
 
 
 
 
Aurora B and the CPC are also required for stability of the bipolar mitotic spindle (Adams et al., 
2001). Furthermore, several studies have shown that Aurora B participates in the control of sister 
chromatid cohesion (Losada et al., 2002) by regulating the association of separase with mitotic 
chromosomes (Yuan et al., 2009). During anaphase, Aurora B concentrates at the spindle midzone and 
equatorial cortex, accumulating ultimately at the midbody where together with all of the CPC components 
plays essential roles in cytokinesis (Terada et al., 1998).. Aurora B is also a key regulator of abscission 
timing if unsegregated chromatin is trapped at the furrow ingression site in human cells (Steigemann et al., 
2009) 
Moreover, Aurora B is a histone kinase that phosphorylates in mitosis histone3 at Ser10 and 
probably 28 and the serine 7 in CENP-A (a modified histone H3 that determine where kinetochores are 
assembled) that seems to be necessary for chromosome condensation and segregation (Giet and 
Glover, 2001) (Nowak and Corces, 2004; Prigent and Dimitrov, 2003) (Johansen and Johansen, 2006). 
Aurora B is also implicated in spindle stability and during cytokinesis. Its local inactivation is necessary for 
completion of abscission (Zeitlin et al., 2001) (Goto et al., 2003) (Guse et al., 2005) (Steigemann et al., 
2009).  
Aurora B is mainly regulated by the interaction with the other CPC components: Incenp, Survivin 
and Borealin. All the CPC members are physically and functionally dependent in a way that when 
knocking down any of the members it delocalizes the others, thus impairing a correct mitotic progression 
(Gassmann et al., 2004; Jeyaprakash et al., 2007).  
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Figure 10. Aurora B regulation. The major regulators of Aurora 
B kinase. Protein kinases are indicated in red and 
phosphorylation events by red arrows. Protein phosphatases are 
indicated in blue. Adapted from (Carmena et al., 2009). 
 
 
 
 
 
INCENP binding to Aurora B increases basal activation of the kinase via its T-loop, which 
achieves full activity by autophosphorylation in a positive feedback loop (Bishop and Schumacher, 2002) 
(Honda et al., 2003). Borealin/Dasra B is suggested to promote local clustering that leads to Aurora B 
auto-activation at the centromere (Sessa et al., 2005) (Kelly et al., 2007). Moreover, phosphorylation of 
Borealin by the checkpoint kinase Mps1 leads to an increased activation of the kinase at the centromere 
which is known to be essential for Aurora B activity and chromosome alignment (Jelluma et al., 2008) 
(Figure 10). Survivin appears to be involved in stimulating Aurora B activity and helps to target Aurora B to 
its substrates (Bolton et al., 2002) (Honda et al., 2003) (Chen et al, 2003). 
Phosphatases negatively regulate the activity of the kinase. It is known that protein phosphatase 
1 (PP1, a ubiquitos serine/threonine phosphatase) and the protein phosphatase 2 (PP2A) are the major 
counteracting phosphatases of Aurora B (Emanuele et al., 2008; Francisco and Chan, 1994) (Sugiyama et 
al., 2002; Sun et al., 2008). In vertebrates at least six different PP1holoenzymes counteract Aurora B 
signaling at the kinetochore. These phosphatases oppose the recruitment (PP1-Mypt1) or retention (PP1α 
and PP1γ/Repoman, localized at the outer kinetochore are able to remove Aurora B phosphorylation 
marks) of Aurora B at the inner centromeres (Trinkle-Mulcahy et al., 2006), or promote the inactivation of 
the kinetochore-associated Aurora B (PP1/Sds22), and dephosphorylation of Aurora B substrates 
(PP1/KNL1, PP1/CENP-E and PP1/KIF18A) (Figure 10). 
During metaphase, when sister chromatids come under tension and PP1 holoenzymes 
dephosphorylate Aurora B thus reversing Aurora B signaling and triggering spindle checkpoint silencing 
(Lesage et al., 2011; Qian et al., 2011). The checkpoint protein BubR1 inhibits Aurora B activity at the 
kinetochore to promote the formation of stable microtubule–kinetochore attachments (Lampson and 
Kapoor, 2005). In anaphase, binding of the microtubule plus-end-binding protein EB1 shields the kinase T-
loop from PP2A dephosphorylation (Sun et al., 2008). Additionally, INCENP dephosphorylation in budding 
yeast by Cdc14 phosphatase upon separase activation has been shown to be important for the transfer of 
the CPC to the central spindle (Pereira and Schiebel, 2003). Indeed, the dephosphorylation of the CPC 
and Aurora B substrates is crucial for completion of mitosis (Lesage et al., 2011). More specific regulations 
of Aurora B are shown in Figure 10. 
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In terms of Aurora B degradation, the kinase is regulated by ubiquitin posttranslational 
modifications. During early mitosis, Aurora B is targeted by a Cul3-containing Scf ubiquitin ligase in order 
to remove a fraction of Aurora B from mitotic chromosome allowing its accumulation on the central spindle 
during anaphase (Sumara et al., 2007). Then, during anaphase Aurora B requires the action of APC/C-
Cdh1 to translocate to the spindle midzone (Floyd et al., 2008). After completion of cytokinesis, the 
remaining pool of Aurora B is targeted for degradation by APC/C-Cdh1 (Floyd et al., 2008; García-Higuera 
et al., 2008). Aurora B proteolysis does not depend on its D-boxes (RXXL), but it does require KEN boxes 
and A-boxes (QRVL) located within the first 65 amino acids (Nguyen et al., 2005). 
 
5.1.3. Aurora C: the unknown member of the family 
 
Whereas Aurora A and B are very well known kinases and ubiquitously expressed in mammals, much less 
is known about Aurora, whose expression is largely limited to germ cells (Carmena and Earnshaw, 2003) 
and at low levels to thyroid and other cell types (Lin et al., 2006) (Ulisse et al., 2006). Aurora C is known to 
have a specific role in spermatogenesis (Yanai et al., 1997), (Tang et al., 2006) (Dieterich et al., 2007b; 
Kimmins et al., 2007b) and in oogenesis (Sharif et al., 2010) but its role in mitosis is still unresolved.  
In terms of its structure, Aurora C is a close paralogue of Aurora B, most probably both proteins 
arose from a relatively recent common ancestor (Brown et al; 2004), in fact, Aurora C has a localization 
pattern similar to Aurora B along mitosis (Dutertre et al., 2005) and can bind members of the CPC 
complex, like Aurora B (Li et al., 2004). Moreover, Aurora C ectopic expression can rescue Aurora B loss 
of function and like other Auroras is activated by some of its substrates, in particular by INCENP (Sasai et 
al., 2004) (Yan et al., 2005) (Slattery et al, 2009). Recently our group described that Aurora C can 
compensate for the lack of Aurora B in somatic cells (Fernández-Miranda et al., 2011). However, in 
interphase Aurora C colocalizes with Aurora A (Dutertre et al., 2005). On the other hand, our group also 
described that Aurora C is the kinase responsible for CPC function during the first embryo divisions (pre-
implantation stage) (Fernández-Miranda et al., 2011). Strikingly, nobody has yet localized the endogenous 
protein nor analysed whether the kinase is expressed in normal somatic cells and what its function would 
be. Additional roles for Aurora C in somatic cells would include non-mitotic functions such as gene 
regulation via histone 3 phosphorylation (Price et al., 2009). 
How Aurora C is regulated is not known so far, but like other Auroras is activated by some of its 
substrates, in particular by association with INCENP (Li et al., 2004; Sasai et al., 2004). Due to the lack of 
KEN and A-boxes motifs, Aurora C is less prone to degradation (Schindler et al., 2012) as was previously 
observed in Hela cells (Sasai et al., 2004). 
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5.2. Mouse models of Aurora kinases 
 
Different mouse models have been generated for the study of Aurora A. In some of them Aurka has been 
genetically ablated (Cowley et al., 2009; Lu et al., 2008; Pérez de Castro et al., 2013; Sasai et al., 2008) 
and its disruption leads to embryonic lethality (E 3.5) due to severe defects in the mitotic spindle. It has 
also been recently described its role in tissue regeneration and tumour development in adult mammals 
(Pérez de Castro et al., 2013). On the other hand, several mouse models have been generated to study 
the effects of its overexpression in different tissues. The last published studies postulate that 
overexpression of Aurora A leads to mammary tumour formation at a low frequency and after a long 
latency and it also contributes to laryngea squasmous cancer progression (Zhang et al., 2008a) (Wang et 
al., 2006). The tumourigenesis associated with Aurora A overexpression is secondary to genetic instability 
that is characterized by centrosome amplification, tetraploidization and PMSC and is also associated with 
an activation of AKT (Bischoff et al., 1998; Zhang et al., 2012). 
The function of Aurora B in vivo has been poorly studied using mouse models. Its role in 
spermatogenesis has been analysed in a mouse model confirming the important role of Aurora B during 
male meiosis (Kimmins et al., 2007b). Recently, our group has generated a conditional knock-out model 
for Aurora B that lead to the discovery of its dispensability during early embryonic development and that 
uncovers and essential role of Aurora C during this stage (Fernández-Miranda et al., 2011). However, the 
effect of Aurora B depletion in adult mammals has not been analysed so far. Moreover, due to the high 
correlation between the expression of Aurora B and the tumourigenicity of several human tumours (see 
Table 1) the study of its overexpression in vivo is crucial to understand the cause of the disease and no 
model to date has been described. 
Regarding Aurora C, a knock-out model for this regulator was generated (Kimmins et al., 2007b). 
The mice were viable and normal but male were infertile, which suggested a role for the kinase in 
spermatogenesis. A recent study in oocytes describes that Aurora C is recruited during oocyte maturation. 
The posttranscriptional regulation of Aurkc mRNA, coupled with the greater stability of Aurora C protein, 
provides a means to ensure sufficient Aurora kinase activity, despite loss of Aurora B, to support both 
meiotic and early embryonic cell divisions (Schindler et al., 2012). However, why germs cells express 
Aurora C is unclear. 
5.3. Aurora kinases and cancer 
 
For tumour formation, cells must acquire a series of genetic alterations that will promote its transformation 
in malignant cells. Several human tumoural analysis and studies in animal models have linked the 
similarity between tumoural formation and Darwin’s evolutive theory. In both cases, successive genetic 
alterations provide a growth advantage that in case of tumours produces the transformation of a normal 
cell into a  
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tumoural one. Tumoural cells not only acquire more proliferative capacity but also the capacity to avoid 
cell death signals, a non-limited potential to duplicate its genetic material, they develop angiogenic 
capacities and also mechanisms to invade adjacent tissues (Hanahan and Weinberg, 2011; Luo et al., 
2009). 
Several evidences relate Aurora kinases with tumoural progression and malignant cell 
transformation. The first studies that link Aurora kinases with tumourigenesis came from the observed 
overexpression of Aurora A and B in primary breast (Sen et al., 1997) and colon samples (Bischoff et al., 
1998; Sen et al., 1997). Aurka is located on human chromosome 20q12, a hotspot of amplification in 
tumours that is also associated with poor prognosis in patients (Sen et al., 1997). Subsequent studies 
identified other human malignant cancers in which Aurka is known to be overexpressed/amplified (Table 
1) and this overexpression has been linked to chromosomal instability (CIN), one of the major drivers of 
the aneuploid state (Perez de Castro et al., 2007; Perez de Castro et al., 2008) (Miyoshi et al., 2001; 
Tanaka et al., 1999). Aurora A, has long been claimed to function as an oncogene in vitro (Bischoff et al., 
1998) and in vivo by inducing mitotic abnormalities (Zhang et al., 2004). 
The role of Aurora B in tumour induction is less clear, although some evidences point to a role for 
the protein in tumourigenesis. In 2006, a computational method that correlates CIN in human tumours with 
several genes expression was developed and Aurka/b were within the CIN70 gene expression signatures 
associated with high chromosome instability (CIN) in human cancers and both genes presented a high 
correlation between their level of expression and the severity of the disease (Carter et al., 2006). 
Moreover, Aurkb, as Aurka, is amplified in primary human tumours where elevated levels of the Aurora B 
transcript or protein are often associated with poor clinical prognosis and correlate with genetic instability 
and metastasis grade (Table 1). Some in vitro studies have demonstrated that forced expression of Aurora 
B can enhance Ras-induced cell transformation (Kanda et al., 2005). A number of studies in in vitro or 
xenografts experiments have shown that Aurora B overexpression induces aneuploidy and increases 
invasiveness, suggesting its role as promoter of metastasis (Ota et al., 2002; Tatsuka et al., 1998; Terada 
et al., 1998) (Steigemann et al., 2009). Furthermore, several studies suggest that tetraploidy is an 
important mediator of Aurora B induced tumourigenesis (Nguyen et al., 2009). In a similar manner, it has 
been hypothesized that Aurora B is a critical target through which overexpressed Bub1 drives 
aneuploidization and tumourigenesis (Ricke RM et al., 2011). However, the causal connection between 
Aurkb abnormal expression, aneuploidy and cancer has not been proved so far.   
Little is known about the third member of Aurora kinase family. In normal physiological conditions 
Aurora C is expressed only in testis (Hu et al., 2000). However, Aurora C is also overexpressed in cancer 
cell lines (Kimura et al., 1999), where its expression is correlated with the aggressiveness of the tumour 
(Table 1). The first evidence of its overexpression was observed in thyroid tumours (Ulisse et al., 2006).  
In vitro, overexpression of AuroraC gives rise to polyploid cells. And like for the other Aurora kinases, the 
phenotype is aggravated in the absence of p53 (Dutertre et al., 2005). 
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Aurora kinases are relevant cancer targets in the clinic. Several inhibitors have been developed 
(Taylor and Peters, 2008) (Malumbres and Perez de Castro, 2014). Most aurora kinase inhibitors are 
small molecule compounds designed to bind to the ATP-binding pocket in a competitive and reversible 
manner. Around 10 pan-Aurora inhibitors have been reported in clinical trials or preclinical stages for 
cancer treatment (Giles et al, 2013, Foran, 2014). The first and best described compounds were 
Hesperadin, VX-680 and ZM447439 (Ditchfield et al., 2003; Harrington et al., 2004; Hauf et al., 2003). 
These three compounds produce cytokinesis failure and and polyploidy. Treatment of mice with VX-680 
efficiently reduces tumour growth in xenograft mice with established tumours, also induces apoptosis and 
reduces histone H3 phosphorylation (Harrington et al., 2004). More recently, Danusertib and AT9283 are 
being used in the clinic as Aurora pan inhibitors (phase I and II clinical trials) (Meulenbeld et al, 2012, Dent 
et al, 2013). Particularly, several Aurkb selective inhibitors have recently being used in the clinic (phase I, 
II and III): BI811283, AZD1152, GSK1070916 (Malumbres and Perez de Castro, 2014). 
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Table 1. Human cancers with alterations in Aurora kinases expression levels. 
 
    AURORA KINASE  A                                                             AURORA KINASE  B                                                               
AURORA KINASE C 
Type of cancer     Alteration Reference 
Colon Overexpression/ 
correlation 
(Katayama et 
al., 1999) 
Astrocytomas Expression/ 
correlation 
(Araki et al., 
2004) 
Seminomas Correlation (Chieffi et al., 
2004) 
Non-small lung 
carcinoma 
Genetic instability 
correlation 
(Smith et al., 
2005) 
Prostate Malignancy/ 
proliferation 
correlation 
(Chieffi et al., 
2006) 
Thyroid Overexpression 
correlation 
(Sorrentino et 
al., 2005) 
Lymph node Invasion (Vischioni et 
al., 2006) 
Breast Elevated 
expression 
(Hegyi et al., 
2012) 
Head/neck SCC Prognostic factor (Pannone et 
al., 2011; Qi et 
al., 2010) 
Hepatocellular 
carcinoma 
Predictive factor 
for recurrence 
(Tanaka et al., 
2008) 
Mammary 
epitelial tumour 
Overexpression in 
nude mice 
(Nguyen et al., 
2009) 
  
Type of 
cancer Alteration        Reference 
Breast Overexpression (Miyoshi et al., 2001; 
Tanaka et al., 1999) 
Colon Overexpression (Bischoff et al., 1998; 
Katayama et al., 1999; 
Sen et al., 1997) 
Pancreas Overexpression (Li et al., 2003) 
Ovary Overexpression (Do et al., 2014) 
Bladder Urinary  
prognostic marker 
(de Martino et al., 
2014; Lei et al., 2011; 
Sakakura et al., 2001) 
Neuro-
blastoma 
Overexpression (Zhou et al., 1998) 
 
Type of 
cancer 
      Alteration Reference 
Thyroid Overexpression (Ulisse et al., 2006) 
(Wiseman et al., 2007) 
Breast Overexpression (Zekri et al., 2012) 
Prostate Gene amplification 
Overexpresion 
biomarker 
(Dhanasekaran et al  
Zekri et al., 2012) 
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Objectives 
 
 
The aim of the work presented in this thesis was to study the in vivo consequences of Aurora B/C 
deregulation in mammals. This work has been focused on the study of the functional characterization 
caused by Aurora B depletion or overexpression by using conditional mouse models, as well as on 
analysing the role of Aurora C, the unkown member of the family, in stemness induction. With this purpose 
the following objectives have been proposed: 
 
1. Understand the in vivo effects of Aurora B depletion in adult mammals. 
 
2. Study the physiological outcomes of Aurora B overexpression in culture cells and adult 
mammals. 
 
3. Explore whether the tumour suppressor function of the p53 pathway is compromised by 
the overexpession of Aurora B. 
 
4. Determine the role of Aurora B and C in pluripotency. 
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Objetivos 
 
 
El principal objetivo del trabajo presentado en esta tesis fue estudiar las consecuencias de la 
desregulación de Aurora B/C en mamíferos. Este estudio se ha centrado en la caracterización funcional 
causada por la depleción/sobreexpresión de Aurora B utilzando modelos condicionales de ratón, así como 
el análisis del papel de Aurora C, miembro desconocido de la familia, en la inducción de la condición 
pluripotente. A partir de este objetivo principal se han propuesto los siguientes objectivos:  
 
1. Comprender los efectos de la eliminación de Aurora B en mamíferos adultos. 
 
2.  Estudiar las consecuencias fisiológicas de la sobreexpresión de Aurora B en células en 
cultivo y mamíferos adultos. 
 
3. Investigar si la function del supresor tumoral p53 está comprometida por la 
sobreexpresión de Aurora B.  
 
4. Determinar el papel de Aurora B and C en pluripotencia. 
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Material and Methods 
1. Genetically modified mouse models 
1.1. Animal housing 
Mice were housed in the pathogen-free animal facility of the Centro Nacional de Investigaciones 
Oncológicas (CNIO, Madrid) following the animal care standards of the institution. These animals were 
observed daily and sick mice were euthanized humanely in accordance with the Guidelines for Humane 
End Points for Animals used in biomedical research. All animal protocols were approved by the ISCIII 
Committee for animal care and research. Mice were maintained in a mixed 129/Sv (25%) x CD1 (25%) x 
C57BL/6J (50%) background).  
1.2. Generation of mouse models 
1.2.1. Construction of targeting vectors 
 
A conditional loss-of-function model of Aurkb was generated in our laboratory (Fernández-Miranda et al., 
2011). The knock-in targeting vector that gives inducible expression of Aurora B gene under a minimal 
tetracycline promoter was constructed by Gonzalo Fernández-Miranda in our lab in collaboration with 
Earnshaw’s lab using a modified version of Ptre-tight vector (Clontech). This modified Ptre-tight vector 
contains the puromycin gene sequences driven by the β-actin promoter for positive selection of the clones. 
Genomic sequences of 5’ and 3’ homology arms were amplified by PCR from previous BACs and cloned 
in PGEM-T (Promega) intermediate vector. The cassette PGK-TK was amplified from Ppnt vector and was 
used for negative selection of the clones. The 5’ arm was then cloned in Ptre modified vector using 
AvrII/SpeI restriction sites, the 3’arm was cloned in PvuII/NotI and the PGK-TK cassette in ClaI/ClaI 
(Figure 12). 
 
1.2.2. Generation of Aurora B conditional, knock-in and null alleles  
 
To facilitate homologous recombination, mouse ES cells V6.4 obtained from a hybrid (129 x C57BL/6J) 
strain were electroporated with 100 µg of linearized DNA from the corresponding targeting vectors. 
Recombinant ES cells and clones were selected in the presence of G418 (neomycin). This step was done 
by the Transgenic Unit of the CNIO. The screening of the recombinant clones was performed by Southern 
blot analysis using new restriction sites from the recombinant alleles and probes external to the homology 
arms. Positive recombinant clones were either aggregated with morulas CD1 or microinjected into 
C57BL/6J blastocysts by the Transgenic Unit of the CNIO. The resulting male quimeras were crossed with 
wild-type females for transmission of the recombinant allele. 
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 Heterozygous recombinant mice Aurkb+/loxfrt (conditional knock-out model) were first crossed with 
TgpCAG-Flpe transgenic mice (Rodríguez et al., 2000) that ubiquitously expressed Flp recombinase, to 
remove the neo selection marker and thus, to generate the conditional Aurkb(lox) allele. To generate the 
null allele we crossed Aurkb+/lox mice with TgCMV-Cre transgenic mice (Zuazua-Villar et al., 2014) that 
ubiquitously expressed Cre recombinase. In the Aurkb(lox) allele, Cre mediated recombination between 
the two loxP sites excises exons 2-6. By tamoxifen treatment Aurkb allele is conditionally depleted.  
On the other hand, for the generation of the inducible Aurora B knock-in mouse, the “hijack” 
promoter strategy was used (Samejima et al., 2008). The conditional targeting construct contained a 
minimal tetO-CMV promoter (Tet-P) inserted in front of the Aurkb ATG, thus replacing the Aurora B 
endogenous promoter, and a puromycin cassette for positive selection of the clones (Figure 12). In the 
case of the inducible mice, after homologous recombination (HR) in ES, clones were selected using 
puromycin resistance. Aurkb+/loxtet clones were identified using Southern blot analysis (Figure 12a). These 
ES cells were aggregated to generate Aurkb+/loxtet mice and the puromycin-resistant cassette was removed 
in vivo by crossing with transgenic mice expressing the Cre recombinase resulting in the Aurkbtet allele. 
The Aurora B inducible mice were then crossed with mice expressing the Rosa26-rtTA allele (Beard et al., 
2006), which expresses a tetracycline-inducible M2rtTA transactivator driven from the endogenous 
ubiquitous Rosa26 promoter (Rosa26M2rtTA/M2rtTA). Addition of tetracycline modifies the configuration and 
binding of rtTA to the tetO sequences so that rtTA binds to and activates expression of the tet-P (Tet-ON 
system) (see Figure 13). Tumor latency in all animals has been considered equivalent to lifespan. 
i4F (four Yamanaka factors) mice were reported previously and were obtained from M.Serrano’s 
laboratory with the purpose of obtaining mouse embryonic fibroblasts (MEFs) to induce pluripotent cells 
(Abad et al., 2013). 
 
1.2.3. Mice genotyping 
 
For genotyping alleles for the different mouse models we isolated tail DNA from 3-4 week old mice and we 
performed a PCR amplification reaction using the oligonucleotides shown in Table 2 using these 
conditions: 94ºC during 4 minutes followed by 35 cycles of DNA denaturalization at 94ºC during 30 
seconds, primer annealing at 60ºC during 30 seconds and polymerase extension at 72ºC during 60 
seconds, ending with a single elongation cycle of 7 minutes at 72ºC. 
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Table 2. Oligonucleotides used for mouse models locus genotyping.  
Mouse Model Allele Size (bp) Sequence (5´-3) 
Aurkb conditional knockout Aurkb(+) 
Aurkb(lox) 
UbCre(+) 
UbCre(T) 
358 
491 
495 
390 
Fw: AGGGCCTAATTGCCTCTTGT 
Rv: GGGCATGAATTCTTGAGTCG 
Fw:CACCCGTTCTGTTGGCTTAT 
Rv: ATGTTTAGCTGGCCCAAATG 
Aurkb inducible knockin Aurkb (+) 
Aurkb(lox) 
Aurkb(tet)                                         
 
Rosa26(+)                         
Rosa26(KI)      
         482 
         430 
368
 
600
         400 
Fw: AGTAGTCTCTGCCCCCTGGT 
Rv_1: GAGATGGGTTGGGTAGCAGA 
Rv_2: ATGGGGAGAGTGAAGCAGAA 
Rv_3:CTGATAGGGAGTAAACTCGACA 
Fw-:GGAGCGGGAGAAATGGATATG 
Rv1:AAAGTCGCTCTGAGTTGTTAT 
Rv2:GCGAAGAGTTTGTCCTCAACC 
4 Yamanaka’s factors OSKM(+) 
OSKM(KI) 
408 
300 
Fw: GGATGGAGTGGGACAGAGAA 
Rv: GTGCCGATCCGTTCACTAAT 
 
 
1.2.4. Treatments in live animals 
 
In order to deplete Aurkb in the conditional model mice were fed with tamoxifen since weaning (previously 
treated with an accommodation diet). To specifically remove Aurora B in the skin, wild-type and transgenic 
mice were anesthesized previous to hair removal (performed as previously described (Ruzankina, 2007) 
and tamoxifen was applied topically during 6 days. For Aurkb induction, mutant and wild type mice (as 
controls) were fed with doxycycline-supplemented food (Harlan Laboratories Models) since weaning (long 
treatment). 
1.3. Histology 
For histological analysis, dissected organs were fixed overnight in 10% buffered formalin (Sigma) and 
embedded in paraffin wax. Specimens were dehydrated in 70% ethanol and processed by the 
Histopathology Facility Unit at CNIO. Sections of 3-5 µm thickness were stained with hematoxylin and 
eosin (H&E). Additional inmunohistochemical examination of the tissues and pathologies was performed 
using specific antibodies against the antigens described in Table 4. To quantify positive cells in the 
different organs, paraffin sections stained with antibodies were examined by using an Olympus BX51 
microscope equipped with objective lenses (40/0.75, 20/0.4, 10/0.25, and 4/0.1). Images were analyzed by 
ImageJ software (National Institutes fo Health, Bethesda, Maryland, USA). Total number of cells was 
counted in each 20X observation field. The pathological analysis was performed with the help of Marta 
Cañamero and Alba de Martino (Histopathology Unit of the CNIO). Hematopoietic parameters in blood 
samples were obtained using an Abacus Junior Vet Hematology Counter (Practice CVM).  
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1.4. In vivo isolation of peripheral lymphocytes and splenocytes 
 
1.4.1. Lymphocytes and splenocytes isolation 
 
Peripheral blood lymphocytes were extracted from wild-type and inducible doxycycline treated mice along 
the time of treatment. Blood was extracted from the cheek of mice and right away lymphocytes were 
isolated by means of Lymphocyte-M cell separation medium (Cedarlane). Lymphocyte-M is a density 
separation medium specifically designed for the isolation of viable lymphocytes from murine lymphoid cell 
suspensions. Cytospin preparations from these samples (interphasic lymphocytes) were analysed by 
Chromosome Fluorescent In Situ Hybridization (FISH). 
Splenocytes were isolated as follows: Mice were euthanized; spleens were extracted and 
maintained in PBS. With the help of a cellular sieve (40 µm; Bencton-Dickinson) the spleen was 
disgregated and homogenized. A total number of 107 cells were plated in six well plates to maintain cells 
at high density. In order to stimulated splenocytes to enter cell cycle, they were cultured in RPMI (Gibco) 
with the addition of concanavalin A (3 µg/ml; conA, Sigma) and Lipopolysaccharide (25 µg/ml, LPS, 
Sigma) during 96 hours.  
 
1.4.2. Karyotyping and scoring of aneuploidy 
 
Cultured cells were exposed to colcemid for 5 hours and hypotonically swollen in a 40% full medium, 60% 
tap water for 5.5 minutes. Hypotonic treatment was stopped by adding an equal volume of Carnoy’s 
solution (75% pure methanol, 25% glacial acetic acid), cells were then spun down and fixed with Carnoy’s 
solution for 10 minutes. After fixation, cells were dropped from a 5-cm height onto glass slides previously 
treated with 45% of acetic acid. Slides were mounted with ProLong Gold anti-fade reagent with 4,6-
diamidino-2-phenylindole (DAPI; Invitrogen), and images were acquired with a Leica D3000 microscope 
and a 60 PlanApo N 1.42 N.A. objective. The karyotyping was performed by counting the number of 
chromosomes from 50 cells per genotype using ImageJ software.  
Peripheral blood lymphocytes were analyzed by FISH using probes from two mouse BAC clones 
(a gift from A. Losada, CNIO) of chromosome 8 (RP23-310L10) and chromosome 11 (RP23-263C13) 
were labeled with SpectrumGreen-dUTP, and SpectrumRed-dUTP (Vysis), respectively. The BAC DNAs 
were labeled by nick translation (Abbot Inc.) according to standard protocols. FISH probes were denatured 
by incubation for 5 min at 90C and then applied to dried slides, before a coverslip was added and sealed. 
Slides were incubated overnight at 37C in a humidified chamber and then washed for 5 min in 50% 
formamide in SSC 2x and for 3 min in 4x SSC + 0.05% Tween 20, all at 45C. Cells were stained with 
DAPI and and mounted using Prolong. Image stacks were acquired on a Nikon Eclipse TE 2000-E 
inverted spinning disk confocal microscope and flattened into a maximal projection before being scored. 
Both gains and losses of chromosomes were counted.The number of hybridization signals for these 
probes was assessed in a minimum of 100 interphase nuclei with well-delineated contours. For performing 
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FISH in tissue sections, paraffin slides (3 µm thick) were pre-treated. First, the slides were immersed in 
xylene for 2 x 20 min, and then for 1 min each in 100%, 85%, and 70% ethanol. Slides were washed in 
running tap water and immersed in ddH2O before being pretreated with 0.2 N HCl for 20 min, washed in 
ddH2O for 3 min, incubated in 8% sodium thiocyanate for 30 min at 80C, washed in 2xSSC for 3 min, and 
digested in 0.5% pepsin in 0.2 N HCl for 1 hr at 37C. Slides were washed at 37C in ddH2O for 1 min and 
in 2 x SSC for 5 min and then dehydrated for 1 min each in 70%, 85%, and 100% ethanol. Slides were 
dried in a 45C oven before being denatured in 70% formamide in 2x SSC at 55 C for 40 s. Denatured 
slides were placed in ice-cold 70% ethanol and then room temperature 70%, 90%, and 100% ethanol for 3 
min each. Slides were then air dried before hibridization with the probes was performed. 
 In addition, aneuploidy was determined by measuring nuclear volumes in tissues. Interphasic 
nucleus volumes were calculated using the following algorithm: 4/3_p_r3, where r ¼ is the Feret 
diameter/2. Feret diameter was calculated using ImageJ on images of DAPI-stained fibroblasts or H&E-
stained tissues (Pérez de Castro et al., 2013) 
 
2. Cell Culture 
2.1. Mouse embryonic fibroblasts (MEFs)  
 
Mouse embryonic fibroblasts (MEFs) were prepared from E13.5 embryos and cultured using standard 
protocols (García-Higuera et al., 2008). E13.5 embryos were extracted from the uterus of pregnant 
females. The placenta was removed and embryos were isolated from the yolk salk. The embryo without 
the liver and the head was minced, and dispersed in 0.1% trypsin (5 min at 37°C). Cells were grown for 
two population doublings and then frozen. All cultures were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM; Gibco) supplemented with 1% penicillin/streptomycin and 10% fetal bovine serum (FBS). 
MEFs infection was performed during 2 days using adenoviruses expressing histone H3 tagged witht the 
green fluorescent protein (H3-GFP) obtained from the University of Iowa (Iowa city, IA).  
For growth curve assays, 50,000 cells were plated in triplicate and were treated with doxycycline 
or left untreated. The number of cells was counted on a daily basis for a week of treatment. The following 
drugs were used in cultured cells at the indicated concentrations: nocodazole (Sigma; 3.5 μM); taxol 
(Sigma; 1 μM), reversine (Sigma; 1 μM), ZM447439 (ZM1, 2 µM, Tocris Biosciences). Immortalization was 
achieved by retroviral infection with a plasmid enconding the first 121 aminoacids of the SV40 large T-
antigen (T121) following hygromycin selection. To induce Aurora B expression, doxycycline was added at 
a final concentration of 1 μg/μl (D-9891, Sigma-Aldrich). Immortal murine MEFs were treated with 
doxycycline for a minimum of 24 hours in order to induce Aurora B expression. Wild-type or Aurora B 
inducible MEFs (untreated or doxycycline treated) were subjected to karyotyping as described in the 
previous section. 
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2.2. Induced pluripotent stem cell generation 
 
Induced pluripotent cells (iPCs) were generated from i4F MEFs (Abad et al., 2013). In order to induce 
pluripotent cells the i4F MEFs were treated at passage 2 with iPCs medium consisting on: 15% of 
KnockoutTM SR Serum Replacement for ES Cells, (Invitrogene, 10828-028; Lot. 719720), 1% non-esential 
aminoacids, 1% penicillin/streptomycin, 0.2% of 2-mercaptoethanol, and 0.1% LIF (103 u/ml final 
concentration). Doxycycline (1 μg/μl) was added to the iPCs medium for 15 days to induce the four 
Yamanaka’s factors. Medium was changed every 1.5 days. Colonies were picked at day 15 and cultured 
in 96 well-feeders plate and were daily observed and subsequently passed.  
2.3. Virus production and cell transduction 
Lentiviruses and retroviruses were produced and concentrated as previously described (Tiscornia et al. 
2006). Briefly, low passage 293T cells were transfected with the lentiviral vector of interest and the three 
packaging vectors expressing gag, pol and rev proteins necessary for virion production as well the 
envelope protein vsvg. 48 hours post transfection supernatants containing viruses were collected and 
concentrated by centrifugation at 19400 rpm for 2 hours at 20ºC. Viral pellets were resuspended in 1x 
HBSS. This viral preparation is of in vitro grade quality. For retroviruses production, 293T cells were 
transfected with the vector of interest and the packaging vector PCL-Eco. Supernatants were collected 48 
hours post transfection. Packaging vectors are a gift from Dr. Verma´s lab. Transduction of primary MEFs 
were performed by adding 10 mL of concentrated virus (stock 109/mLl viral particles) per million of cells 
(MOI 10) for 12 hours or by using directly the viral supernatants collected from 293T cells repeating the 
virus addition three times for 6 hours.  
 
2.4. Cell transfection 
 
Plasmid transfection in MEFs was performed using Lipofectamine 2000 (Invitrogen) except when using 
OSKM MEFs transfection which was carried out using the Neon technology (Life Technologies; Invitrogen) 
using standard protocols. 
 
3. Microscopy techniques 
3.1. Live cell imaging 
 
For time-lapse imaging experiments, synchronous, histone H2B-GFP-expressing inmortal MEFs were 
recorded using a computer- assisted microscope (images were adquired every 10-minute frames during 
48 hours). Cells were prepared and after being plated on eight-well glass-bottom dishes (Ibidi). Video 
started after 18 hours upon doxycycline addition.Drugs were just added 2 hours before the video start. 
Time lapse acquisition was performed with a DeltaVision RT imaging system (Applied Precision; IX70/71;  
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Olympus) equipped with a charge-coupled device camera (CoolSNAP HQ; Roper Scientific) and a plan 
Apochromatic 40×/1.42 N.A. objective lens, and maintained at 37°C in a humidified CO2 chamber. Images 
were analyzed using ImageJ software (National Institutes of Health, Bethesda, Maryland, USA, 
http://rsb.info.nih.gov) in order to determine the duration of mitosis (DOM). 
3.2. Inmunofluorescence 
 
The protocol for inmunofluorescence in cultured cells was adapted from (Perera et al., 2007). Adherent 
cells grown in coverslips were fixed for 7 min in freshly prepared 2.0% formaldehyde/PHEM at 37C 
(preheated). Cells were rinsed three times for 5 min with PBS containing 0.05% Tween-20 (PBST) and 
permeabilized in preheated 0.5% Triton X-100 for 10 min at 37C. Then cells were subsequently blocked 
for 45 min-1hour at RT in BSA1% PBS 1% and incubated overnight at 4C in a humid chamber with 
primary antibodies (shown in Table 4). The following day, after four 5-min rinses in PBST, cells were 
incubated for 45 min at room temperature in the dark, in secondary donkey anti–rabbit and anti-mouse 
antibodies at 1:250 (Jackson ImmunoResearch Laboratories), rinsed with PBST and stained with DAPI. 
Matching secondary antibodies with different Alexa dies (488, 594, 647) (Table 3).  and DAPI for nuclei 
visualization were from Molecular Probes (4,6 diaminophenylindole, Prolong Gold antifade; Invitrogen). 
Image acquisition was performed using either a Leica D3000 microscope or confocal ultraspectral 
microscope Leica TCS-SP5-AOBS-UV.  
 
Table 3. Secondary antibodies used in IF experiments. 
 
Antibody Type IF Source/Clone 
Alexa Fluor-488  Donkey/goat anti-rabbit IgG (H+L) 1:1000 Invitrogen 
Alexa-Fluor- 488 Donkey/goat anti-mouse IgG (H-L) 1:1000 Invitrogen 
Alexa-Fluor- 594 Donkey/goat anti-mouse IgG (H-L) 1:1000 Invitrogen 
Alexa-Fluor-594 Donkey/goat anti-human IgG (H-L) 1:1000 Invitrogen 
 
 
4. Flow cytometry 
 
For DNA content analysis, cells were fixed in 70% ethanol overnight at -20C. The following day cells were 
stained with propidium iodide (20 mg/mL; Sigma) in presence of RNAseA (0.2 mg/mL; Qiagen) for 
30minutes at 4C and then analyzed by flow cytometry (Becton- DickinsonFranklin Lakes, NJ, USA). In 
order to determine S phase entry in splenocytes upon cell cycle stimulation entry with ConA and LPS, Edu 
analysis was performed. Cells were pulsed with EdU (10 µM, Sigma) for 30 minutes and then fixed in 70%  
Material and Methods   
 
 
42  
ethanol overnigth at -20ºC. The following day, DAPI (2 µg/ml, Sigma) was added and cells were analyzed 
by flow cytometry (Becton-Dickinson). Flow cytometric analysis was performed with a FACS-Canto flow 
cytometer or a LSRII flow cytometer (BD Biosciences) and FlowJo Version 8.8.7 software was used to 
analyze cell populations (TreeStar). 
 
5. Biochemical procedures 
5.1. RNA extraction and Real-Time PCR 
 
To quantify expression of transcripts, total RNA from cells and tissues was isolated using Trizol 
(Invitrogen). Expression of Aurkb and p21Cip1 was quantified by real-time quantitative amplification with the 
SuperScript® III Platinum assay kit, according to the manufacturer’s instructions, in a BioRad iCycler Real-
Time PCR apparatus. The following primers were used: Aurkb FW: 5’-ATGGCTCAGAAGGAGAACGC-3’, 
Aurkb RV: 5’-CCAGTTCCCACCCCTTCT-3’; p21Cip1 F 5’-CTAGGGGAATTGGAGTCAGGC-3’, p21Cip1 RV: 
5’-AACAGGTCGGACATCACCAG-3’. Amplification of α-GAPDH was used for normalization using the 
following oligonucleotides: GAPDH FW: 5’-GCCACCCAGAAGACTGTGGATGGC-3’, GADPH RV: 5’-
CATGATGGCCATGAGGTCCACCAC-3’. Data analysis was performed using the iQ5 v.2.0 software 
(BioRad). 
 
5.2. Protein extraction and analysis 
 
For immunodetection in protein lysates, cells and tissues were washed twice with ice-cold PBS and lysed 
in RIPA lysis buffer (37 mM NaCl, 0.5% NP-40, 0.1% SDS, 1% TX-100, 20 mM Tris-HCl pH 7.4, 2 mM 
EDTA, 10% glycerol 1 mM PMSF) or Laemmli buffer supplemented with protease and phosphatase 
inhibitory cocktails (Sigma). In the case of Ripa buffer, after 30 minutes on ice, samples were cleared by 
centrifugation, whereas Laemmli samples were directly denatured for 10 min at 95 degrees. 50 μg of total 
protein were separated on SDS-PAGE, transferred to nitrocellulose membranes (BioRad), and probed 
using specific primary antibodies that are noted as WB in Table 4. Secondary antibodies were coupled to 
HRP (DAKO) for immunodetection. 
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Table 4. Primary antibodies used in different assays. 
 
Antibody Host Species/Clonality Application Dilution Source/Clone 
ACA Human (P) IF 1:500 Antibodies Inc. 
α-Actin Mouse (M) IF, WB 1:2000 Sigma / DM1A 
Aurora B Rabbit (P) IF,IHQ,IP,WB 1:200 Abcam 
Bax Rabbit (P) WB 1:200 Millipore 
β-tubulin Mouse (M) WB 1:2000 Sigma/AC-40 
Bromo-deoxyuridine Mouse monoclonal IHQ 1:50 GE Healthcare/BU-1 
BubR1 Sheep IF 1:100 S.Taylor (gift) 
 Caspase 3 active Rabbit polyclonal IHQ 1:200 RYD systems 
CD3e (M-20) Goat polyclonal IHQ 1:500 Santa Cruz Biotec. 
Cdk1 Mouse monoclonal IP 1:200 Santa Cruz Biotec. 
Cyclin B1 Rabbit polyclonal WB  1:500 Santa Cruz Biotec. 
Incenp Rabbit polyclonal WB 1:1000 Cell Signaling 
Ki67 Rat monoclonal IHQ 1:100 GE Healthcare 
Mad2 Rabbit polyclonal IF 1:200 K.Wassmann (gift) 
Pax5 (C-20) Goat polyclonal IHQ 1:500 Santa Cruz Biotec. 
Phospho-CENPA(ser 
7) Rabbit polyclonal WB, IF 1:200 Rabbit polyclonal 
Phospho-Histone H3 
(Ser10) Rabbit polyclonal WB, IHQ 1:500/1:2000 Upstate Biotec. 
γ-H2A.X (Ser139) Mouse monoclonal WB, IHQ 1:1000 Millipore / JBW30 
Phospho-Th232-
Aurora B Rabbit polyclonal WB, IF 1:200 Rockland 
Phospho-p53 (Ser15) Rabbit polyclonal WB,IHQ 1:500 Cell Signaling 
P21Cip1 Mouse monoclonal WB;IHQ 1:1000 Santa Cruz Biotec. 
P53 Mouse monoclonal WB 1:1000 Cell signaling 
Plk1 Mouse monoclonal IP 1:200 Abcam 
PUMA Rabbit polyclonal WB 1:500 Abcam 
Survivin Rabbit polyclonal WB 1:500 Novus Biologicals 
Vinculin Mouse WB 1:5000 Sigma 
P: polyclonal, M: monoclonal; Immunohistochemistry (IHQ), Immunofluorescence (IF), Immunorecipitation (IP) and 
Western blot (WB)  
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6. DNA damage assays 
 
To induce DNA damage, Aurkb+/+Rosa26M2rtTA/M2rtTA  and Aurkb+/tet Rosa26M2rtTA/M2rtTA  immortal murine 
MEFs were treated with doxycycline for 24 hours in order to induce Aurora B. 1 µM Adryamicin was then 
added for two hours to induce p53 signaling. Samples were taken 6 and 10 hours post-Adryamicin 
treatment. For inducing DNA damage in vivo, Aurkb+/+; Rosa26M2rtTA/M2rtTA and Aurkb+/tet Rosa26M2rtTA/M2rtTA 
mice were treated for fifteen days with doxycycline and unanaesthestized animals were restrained in well-
ventilated perspex boxes and whole body exposed to a single dose of 8 Gy gamma radiation. Animals 
were sacrified 24 hours after the irradiation procedure. Labeling retaining experiments (BrdU) were based 
on previously reported procedures (Braun et al., 2003).  
 
7. Physiological and metabolic assays 
 
7.1. Dual Energy X-ray Absortiometry (DEXA) 
 
The percentage of body lean mass was determined from whole-body samples (excluding cranial region) 
using a Lunar Piximus densitometer (GE medical systems) with a high degree of accuracy. DEXA was 
performed just before the metabolic measures (OXYLET) were taken. 
 
7.2. Metabolic cages 
 
The Oxylet (Harvard Apparatus) allowed us to measure three different parameters related to metabolism: 
1. Indirect calorimetry; 2. Food/drink intake; 3. Locomotive activity. 1. Indirect calorimetry is a method used 
to measure the energy consumption of animals. It is based on the calculation of the energy produced by 
the cellular metabolism through the products of respiratory exchange. The apparatus monitors respiratory 
metabolism: O2 consumption and CO2 production and from these parameters we calculated the respiratory 
quotient (RQ), which is calculated by dividing Vc02 production/VO2 consumption. These values were used to 
calculate the mice energy expenditure (EE). The equation used for this calculation is the semi-empirical 
Weir Equation. EE is given in kcal/day kg·3/4 (Weir, 1949). 2. Food and drink consumption was measured 
the whole day. These data were always relating to the total body weight of the mouse or the total body 
lean mass. 3. Locomotive activity was measured by analyzing two parameters: mean spontaneous activity 
of the mouse along the cage and number of rearings. 
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8 Statistical and imaging analysis 
 
Statistical analysis was performed using Student’s t-test, Fisher’s exact test, or log-rank tests (GraphPad 
Prism 5). EE was analysed by using ANCOVA and the variable weight as co-variant. All data are shown 
as mean ± SEM. Probabilities of p<0.05 or alpha<0.05 (Fisher’s exact test) were considered significant. 
Images were quantified using ImageJ. In most figures, *, p<0.05; **, p<0.01; ***;p< 0.001. 
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Results 
Aurora B function has been extensively studied in yeasts, nematodes, insects and cold-blood vertebrates 
but very limited information concerning the Aurora B role in mammals and its implication in tumourigenesis 
is available. To study the in vivo function of Aurora B in mammals, two different mouse models were 
generated in our laboratory originally by Fernández-Miranda G.: a conditional knock-out model and a 
tetracycline inducible model (Figures 11 and 20). 
1. Conditional Aurora B depletion model 
1.1. Generation of conditional Aurora B depleted mice 
The conditional knock-out model was generated by using a targeting vector in which Aurora B exons 2-6 
were flanked with loxP sequences and a frt-neor (neomycin-resistant gene)-frtv cassette for selection 
purposes (Figure 11). At both ends of the construct two homology arms were cloned to facilitate HR in ES 
cells. Clones carrying the recombinant allele Aurkb(loxfrt) (Fig 11b) were selected and the corresponding 
ES cells were microinjected in wild-type blastocysts to generate Aurkb(+/loxfrt) mice. The neor cassette 
was first removed by crossing with transgenic mice expressing the Flp recombinase resulting in the 
conditional Aurkb(lox) allele. Deletion of exons was then achieved by additional crosses with CMV-Cre 
transgenic mice to generate Aurkb(-). Elimination of exons in Aurkb(-) allele ensures total inactivation of 
Aurora B since the kinase domain of Aurora B is almost completely removed. By using the conditional 
knock out (cKO) model for Aurora B (Fernández-Miranda et al., 2011), it was observed that the genetic 
elimination of Aurora B in vitro induces problems during prometaphase avoiding the correct segregation of 
chromosomes during mitosis, leading to abnormal interphasic and polyploid cells. Moreover, complete 
ablation of Aurora B is embryonic lethal whereas heterozygous mice are fertile but have shorter lifespan 
(Fernández-Miranda et al., 2011). Here we use this depletion model to study the in vivo effect of the 
complete depletion of Aurora B in adult mammals. 
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Figure 11. Aurora B conditional knockout alleles. (a) Schematic representation of Aurkb null knock-out alleles.The mouse 
Aurkb locus encoding Aurora B contains 8 exons (boxes) containing non-coding (open boxes) or protein coding (filled boxes) 
sequences. Wild-type (white triangles) loxP sites and frt (black triangles) sites are used to flank Aurora B exons or the neo 
resitance in the targeting vector. The neo cassette (black) contains promoter and poly-A sequences and it is used for selection of 
clones after homologous recombination (HR) in ES cells. The neo cassette is eliminated in vivo by crossing Aurkb(+/loxfrt) mice 
with transgenic mice expressing the Flp recombinase. Further excision of exons 2-6 is mediated by expression of the Cre 
recombinase resulting in the Aurkb(-) null allele. The ScaI restriction sites are also shown, 5’ and neo probes and primers 1,2,3 
used for genotyping. (b) Southern blot analysis of recombinant ES cells showing two Aurkb(+/loxfrt) clones that underwent HR. 
DNA was digested with ScaI and hybridized with the probe 5’ or neo specific sequences (Fernández-Miranda et al., 2011). 
 
 
1.2. Decreased survival of Aurora B depleted mice 
 
The effects produced by the ablation of Aurora B in adult mammals have not been studied so far. To 
address this fundamental question, we took advantage of the conditional mouse model for the depletion of 
Aurkb (Fernández-Miranda et al., 2011) that allowed us to study the in vivo defects caused by Aurora B 
depletion in the whole animal. 
We first fed wild type and transgenic mice with tamoxifen for a month in order to ensure that we 
were able to deplete Aurora B in vivo. As shown in Figure 12a, a significant reduction in the expression of 
Aurora B protein in different tissues was observed in Aurkblox/lox; UbCreT  mice. Then, in order to analyse 
the consequences of Aurora B ablation in an adult organism Aurkb++;UbCreT and AurkbloxloxUbCreT mice 
were fed with tamoxifen since weaning for 80 weeks. This significant reduction of Aurora B expression 
compromised the survival of adult mice since by one year of age, almost 40% of the Aurora B-deficient 
mice had died or had to be sacrificed whereas all control mice survived (Figure 12b).  
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Figure 12. Aurora B depletion in adult mice induces decreased survival as a consequence of diminished proliferation and 
increased apoptosis. (a) Aurora B inmunohistochemical detection is shown for the skin, intestine and spleen of wild-type (+/+) 
and Aurora B null (Δ/Δ) mice. Aurora B expression is significantly diminished upon tamoxifen treatment in AurkbloxloxUbCreT mice. 
(b) Aurora B deletion results in lethality.Graph shows the survival curve from 1 to 20 months of tamoxifen treatment. Survival 
curves of Aurkb+/+UbCreT mice (n=10) and Aurkblox/loxUbCreT (n=19) mice were compared using a log-rank (Mantel-Cox) test. ** 
p< 0.01. Scale bars 50 µm.  
 
1.2.1. Impaired proliferation and increased apoptosis in Aurora B depleted mice 
 
When analyzing in more detail several proliferative tissues such as spleen or intestine, we observed that 
Aurora B depletion produced a significant reduction in the proliferation marker Ki67. A detailed analysis of 
these proliferative tissues allowed us also to visualize among the AurkbΔ/Δ tissues a significant increase in 
the levels of the apoptotic marker Active-Caspase3 (AC3) (Figure 13). These data indicated us that Aurora 
B depletion was impairing proliferation and increasing apoptosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Aurora B depletion impairs proliferation and induces apoptosis. Representative pictures of inmunohistochemical 
detection for Ki67 and Active caspase-3 are shown for intestine and spleen of wild-type (+/+) and Aurora B null (Δ/Δ) mice. Ki67 
expression is significantely decreased in both tissues upon tamoxifen treatment in AurkbloxloxUbCreT mice, versus wild-type mice 
(19.98 ± 0.92 v. 15.97 ± 0.63; spleen and 82.68 ± 2.18 v. 59.98 ± 2.19; intestine).CA3 expression is increased in 
AurkbloxloxUbCreT mice, versus wild-type mice (0.41 ± 0.07 v. 0.63 ± 0.06; spleen) (0.14 ± 0.07 v. 0.70 ± 0.15; intestine). Bar 
graphs indicate the quantification of the number of positive cells for Ki67 and Caspase3 (n=3 mice per genotype). Scale bars 100 
µm *, p< 0.05;** p< 0.01; *** p< 0.001. 
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1.2.2. Aurora B depleted mice are defective in hematological parameters 
 
Defects in bone marrow, such as medullar fibrosis and loss of cellularity were characteristic of null mice for 
Aurora B. When analyzing peripheral blood, red and white blood cells were significantly reduced in the 
Aurora B depleted mice after 60 weeks of tamoxifen treatment (Figure 14a), which is in accordance to the 
lack of cellularity in the medulla. Moreover, We observed lack of proliferation and increased apoptosis in 
the bone marrow of AurkbΔ/Δ mice (Figure 14b) No differences in bone density were observed by 
densitometry analysis (data not shown), probably as a consequence of the increase fibrosity of the bone 
marrow.  
 
a                                                                                  b 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Conditional ablation of Aurora B in adult mice affects hematological parameters. (a) Hematological parameters 
in wild-type and Aurora B null mice showing reduced number of white blood cells in the Aurora B null mice (AurkbΔ/Δ). (b) 
Inmunohistochemical detection for Ki67 and Active Caspase-3 is shown in the bone marrow of wild-type (Aurkb+/+) and null 
(AurkbΔ/Δ) mice showing decreased Ki67 expression and increased number of apoptotic cells upon tamoxifen treatment in Aurora 
B null mice. (86.44 ± 2.82 v. 74.07 ± 3.57; Ki67 staining) (0.21 ± 0.00 v. 0.47 ± 0.05; AC3 staining).Bar graphs indicate the 
quantification of the number of Ki67 and Caspase3 positive cells (n=3 mice per genotype). Scale bars 50µm.*, p< 0.05, *** p< 
0.001. 
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1.3. Aurora B depletion leads to aneuploidy and increased p53 response 
 
1.3.1. Lack of Aurora B leads to aneuploidy 
 
The AurkbΔ/Δ spleen red pulp was characterized by the presence of cells with an increased nuclear size 
(anisocariosis) (Figure 15a). This phenotype was also detected in other cell types such as kidney, 
pancreas and liver. The observed anisocariosis was an indication of division defects that may reflect an 
abnormal number of chromosomes caused by the depletion of Aurora B in the whole animal. We also 
analysed aneuploid levels among the ageing mice; peripheral blood lymphocytes were taken from control 
and Aurora B depleted mice and interphasic nuclei were subjected to fluorescence in situ hybridization 
(FISH) analysis using probes against chromosomes 8 and 11. The percentage of aneuploidy, calculated 
as the deviation from the mode, was not significantly different when analyzing Aurkb+/+ and AurkbΔ/Δ mice 
aged for 4 months (p=0.08). At 20 months of age, these numbers increased and the difference between 
both genotypes was statistically significant (3.6% of aneuploidy in Aurkb+/+ and 9.7% of aneuploid cells in 
Aurkb+/tet mice (*,p= 0.0447). Age-dependent accumulation of aneuploidy in lymphocytes was observed in 
both genotypes although AurkbΔ/Δ animals contained a higher percentage of aneuploidy (Figure 15b). 
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Figure 15. Aurora B depletion leads to aneuploidy. (a) Aneuploidy is a common feature in spleens of AurkbΔ/Δ mice. Nuclear 
size was used to compare DNA content of Aurora B defective and control cells. Images show H&E spleen sections where nuclei 
have been highlighted. Scale bar, 50 µm. Bar graphs shows the quantification of the nuclear volumes of Δ/Δ samples (n= 150 
nuclei per condition) normalized to control cases (2.40 ± 0.09 fold change versus wild-type mice). (b) In vivo aneuploidy study in 
Aurkb+/+ and AurkbΔ/Δ along tamoxifen treatment. AurkbΔ/Δ mice contain high levels of aneuploid cells that are not eliminated from 
the cycling population. Aneuploidy was scored by counting the number of FISH signals per cell in lymphocytes from 4 and 20-
month-old animals (At least n= 100 nuclei per genotype and time point). FISH analysis was performed using probes for 
chromosomes 8 (red) and 11 (green). Dot lines represent aneuploid cells. The percentage of aneuploidy was 1.14 % in Aurkb+/+ 
and 2.69% in AurkbΔ/Δ when the mice were 4 months old (p= 0.08) and 3.6% in Aurkb+/+ and 9.7% in AurkbΔ/Δ when the mice were 
aged 20 months (p= 0.0447). Each column represents one animal. Data are shown as the deviation from the mode. 
Representative FISH images are shown on the right panel. Scale bar,20 μm. *, p< 0.05; ***, p< 0.001. 
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1.3.2. Increased p53 signaling upon Aurora B depletion 
 
Since p53 and its main target p21Cip1 are induced in vitro upon Aurora B depletion (Trakala et al., 2013) we 
decided to test whether depletion of Aurora B in vivo was also accompanied by p53 activation. As 
represented in Figure 16, both p53 and its effector p21Cip1 were upregulated in the spleen of AurkbΔ/Δ mice 
compared to wild-type animals.  
 
 
 
 
 
 
 
 
 
 
Figure 16. In vivo depletion of Aurora B induces p53 signaling. p53 and p21 upregulation by Aurora B. Images and IHC 
quantification from spleen samples collected from Aurkb+/+ and AurkbΔ/Δ mice are displayed. The percentage of positive cells was 
evaluated for p21 and p53. As shown, the percentage of p21and p53 positive cells was higher in AurkbΔ/Δ mice (6.26 ± 0.45 v. 
1.87 ± 0.67; p53 staining) (0.51 ± 0.14 v. 0.15 ± 0.06; p21 staining). Scale bar, 50 μm. .*, p< 0.05; ***, p< 0.001. 
 
1.4. Premature ageing in Aurora B depleted mice 
 
The main phenotype observed among the Aurora B-deficient mice was premature ageing (Figure 17a), 
85% of AurkbΔ/Δ mice presented this phenotype whereas it was not found in any of the wild-type animals 
(Figure 17a). The external phenotypes of AurkbΔ/Δ mice were loss of hair, hair graying and kyphosis, 
hallmarks typically associated with an ageing phenotype (Figure 17a). Histopathological analysis of sick 
mice showed a pleiotropic phenotype preventing us from establishing a single common cause of death in 
all the cases. Several features found in Aurora B null mice such as thinner and disorganized epidermis, 
kidney inflammation and degeneration, extramedullary hematopoiesis, spleen an intestine atrophy, can be 
associated to death as a result of starvation, infection, dehydratation or multiorganic failure. Aurora B 
depleted mice also presented cataracts, adipose atrophy, medullar fibrosis and pancreas, liver and kidney 
anisocariosis (Figure 17b and 17c). The intestine showed decreased number of crypts and villi length. 
Reduced follicles in the spleen of AurkbΔ/Δ could also be observed. 
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Figure 17. Aurora B depletion in adult mice induces premature ageing. (a) Premature ageing incidence found in the Aurora 
B-depleted mice is shown. AurkbΔ/Δ ***, p=0.0001 vs. wild-type mice using Fisher’s exact test. Right panel shows the external view 
of Aurkblox/loxUbCreT and Aurkb+/+UbCreT mice treated with tamoxifen during 50 weeks. (b) Graph shows the percentage of 
incidence of the ageing pathologies found in the Aurora B-depleted mice (c) H&E staining of the indicated pathologies found in 
Aurkblox/loxUbCreT animals: i: skin atrophy; ii: abnrnomal intestine cripts; iii: medullar fibrosis; iv pancreas anisocariosis; v: 
extramedullar hematopoyesis. Scale bar, 50 µm. 
1.5. Aurora B depletion prevents tissue regeneration 
 
1.5.1 Diminished proliferative capacity of Aurora B depleted mice 
 
To investigate the consequences of Aurora B ablation in tissue regeneration in vivo, we made use of the 
hair follicle cycle. Aurkb+/+ and AurkbΔ/Δ mice were subjected to skin hair removal on 2cm3 patches of their 
back skin and were next treated with tamoxifen for 6 days. A week later, control mice were able to 
repopulate their back skin with new hair, this was not the case for AurkbΔ/Δ mice (Figure 18a). Particularly, 
the epidermis of AurkbΔ/Δ mice presented clear cell depletion and hair follicles were mainly in the catagen-
telogen stage without reaching the panniculus carnosus muscle. Aurora B depletion was clearly visualized 
(Figure18a). When analyzing further the skin of the mutant mice we observed a significant increase in the 
number of mitotic cells in the follicle hair, being most of them metaphases; abnormal mitosis such as 
misaligned chromosomes could also be observed in the skin of AurkbΔ/Δ mice. These data indicated us 
that probably Aurora B depletion is causing division defects thus preventing a correct cell division, 
resulting in tetraploidization.  
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Figure 18. Lack of Aurora B affects hair regeneration. (a) Scheme of the protocol followed to test the regenerative capacity of 
Aurora B depleted hair follicles. The back skin of Aurkb+/+ (n=3) and AurkbΔ/Δ mice (n=3) was removed and topically treated with 
tamoxifen. Pictures show how 1 week later, hair recovery was observed in control mice whereas no hair repopulation was 
observed in AurkbΔ/Δ mice. On the right panels, hematosilin and eosin staining (H&E) showing the arrest of hair follicle cycle in 
catagen-telogen stage and Aurkb IHCs showing the depletion of the protein in the skin of transgenic mice.(b) Hematosilin and 
eosin staining shows an increase in the number of mitosis in the skin of AurkbΔ/Δ mice (0.76 ± 0.13 v. 1.66 ± 0.28). On the right 
panel, the percentage of abnormal mitosis (0.003 ± 0.003 v. 0.29 ± 0.15) and pictures showing these defects are shown. Scale 
bar, 200 µm in (a) and 50 µm in (b). **, p< 0.01.   
1.5.2. Lack of stem cells regeneration and apoptosis upon Aurora B depletion 
 
Moreover, a significant increase in the number of apoptotic cells could be observed in the skin of the 
Auora B depleted mice, which impinges on the regenerative capacity of the hair follicles (Figure 19a). 
Moreover, when analyzing the stem cell marker CD34, we found a decrease in the number of positive cells 
for this marker in the Aurora B-deficient mice (Figure 19b). These data indicated us that the lack of Aurora 
B was producing problems in mitosis that lead to an increase in the ratio of apoptotic cells and at the same 
time was affecting the regenerative capacity of stem cells to repopulate the tissue. 
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Figure 19. Aurora B depletion produces lack of stem cell regeneration and induces apoptosis. (a) Inmunohistochemistry 
analysis of the stem cell marker Cd34 is shown in wild-type and Aurora B-depleted mice (1.47 ± 0.05 in wild-type mice v. 5.76 ± 
0.67 positive cells in AurkbΔ/Δ).(b) Percentage of apoptotic cells in the skin of of Aurkb+/+ (n=3) and AurkbΔ/Δ mice (n=3) is 
represented, (51.26 ± 0.52 in wild-type v. 23.87 ± 0.37 AurkbΔ/Δ). Images are shown on the right. Scale bar 100 µm.  
 
2. A model for Aurora B overexpression 
2.1 Generation of an endogenous Aurora B inducible model  
 
Due to the fact that Aurora B is generally over-expressed in a variety of human tumours (Chieffi et al., 
2006) and that its deregulation is related to aneuploidy and therefore to cancer, our goal is to know 
whether Aurora B overexpression can lead to tumour formation through aneuploidy induction. To achieve 
this first objective, a murine allele in which the expression of the endogenous Aurora B gene, Aurkb, can 
be induced in vitro and in vivo was generated in collaboration with Proffesor Earnshaw’s laboratory at the 
Wellcome Trust Center for Cell Biology in Edinburgh. 
To generate a model with inducible expression of Aurora B, the promoter region of the 
corresponding murine gene was genetically modified (Aurkb; Figure 20a). This model is based on the 
hijacking promoter strategy previously used in chicken DT40 cells in which the endogenous Aurkb 
promoter (2 kb upstream of the translation initiation codon ATG of Aurkb gene) is substituted with a 
minimal cytomegalovirus (CMV) promoter-linked with seven in tandem repeats of tetO sequences. These 
sequences are flanked by loxP sites and a puromycin cassette that was used for positive selection of the 
clones (Samejima et al., 2008). This construction leads to a tetO-CMV promoter (Tet-P) that is only active 
in the presence of the binding of the regulatory proteins (rTTA) to the tetO sequences. 
After homologous recombination in ES cells, recombinant clones (Aurkb lox-tet) that were 
puromycin resistant, were selected by Southern blot analysis using the 5’ and neo probes as indicated in 
Figure 20. These clones were aggregated into developing blastocysts togenerate Aurkb+/loxtet mice 
(chimeras were generated through standard blastocyst microinjection). The puromycin-resistant cassette 
was then removed by crossing with transgenic mice expressing the Cre recombinase resulting in the 
Aurkb+/tet mice (Figure 20a). We were not able to obtain homozygous Aurkbloxtet/loxtet or Aurkbtet/tet mutants 
from crosses between heterozygous mice, in agreement with a lethal phenotype caused by the lackof 
Aurora B in embryos. 
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Figure 20. Inducible model for Aurora B in which Aurkb promoter has been replaced by a tetracycline-responsive 
minimal promoter (a) Schematic representation of the alleles used in this study for the inducible overexpression of Aurora B (see 
Matherial and Methods for details). In the Aurkbloxtet allele, the Aurora B endogenous promoter was replaced by a tet-P, a 
minimal CMV promoter that contains seven in tandem repeats of tetO sequences recognized by the transactivator regulatory 
proteins rtTA. The activity of Cre recombinase resulted in the removal of the puromycin-resistance cassette and the generation of 
the Aurkbtet allele. (b) Southern blot analysis of ES cell clones after homologous recombination indicates the presence of the 
recombinant Aurkbloxtet allele in one of the clones. The location of the probe is indicated in (a).  
Finally, to generate an inducible system, the Aurora B inducible mice were crossed with mice 
expressing the Rosa26 (rtTA) allele (Beard et al., 2006), which expresses a tetracycline-inducible M2rtTA 
transactivator driven from the endogenous ubiquitous Rosa26 promoter.  
Addition of tetracycline modifies the configuration and binding of rtTA to the tetO sequences so 
that rtTA binds to and activates expression of the tetP (Figure 21). For Aurkb induction, mutant and wild-
type mice (as controls) were fed with doxycycline-supplemented food so that Aurkb is overexpressed in 
the whole animal. 
 
 
 
 
 
 
Figure 21. Inducible expression of Aurora B (TetON system). The Aurkb(tet) allele contains a minimal tetO-CMV promoter 
(Tet-P) instead of Aurora B endogenous promoter. The tet-P sequences are recognized by transactivator regulatory proteins 
(rtTA). The Rosa26(rtTA) allele generated in (Beard et al., 2006) expresses a tetracycline-inducible M2rtTA transactivator driven 
from the endogenous ubiquitous Rosa26 promoter. Addition of tetracycline modifies the configuration and binding of rtTA to the 
tetO sequences so that rtTA binds to and activates expression of tet-P in the presence of tetracycline (Tet-ON system).  
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2.2. Aurora B overexpression results in mitotic defects and aneuploidy 
 
2.2.1. In vitro characterization of Aurora B overexpressing MEFs 
 
Aurkb+/tet; Rosa26M2rtTA/M2rtTA and Aurkb+/loxtet; Rosa26M2rtTA/M2rtTA mouse embryonic fibroblasts (MEFs) were 
obtained and cultured in the absence or presence of doxycycline. Treatment with doxycycline induced a 
significant increase in Aurora B mRNA and protein levels (Figure 22 a and b). Aurora B was always 
induced to a higher level in Aurkb+/tet than in Aurkb+/loxtet MEFs, and we therefore selected Aurkb+/tet clones 
for further assays. The doxycycline treatment did not alter the localization of Aurora B (Figure 22c) 
indicating that Aurora B overexpressed protein was functional and located properly.  
 
a                                                      b 
 
 
 
 
 
 
 
Figure 22. Aurora B overexpression in MEFs. (a) Quantitative RT-PCR data from Aurkb+/+, Aurkb+/loxtet and Aurkb+/tet cells 
carrying the Rosa26(M2rtTA/M2rtTA) allele in the absence or presence of doxycycline (doxy) for 48h. GADPH was used as 
control of expression. (b) Immunodetection of Aurora B in Aurkb+/loxtet; Rosa26M2rtTA/M2rtTA and Aurkb+/tet; Rosa26M2rtTA/M2rtTA primary 
mouse embryonic fibroblasts (MEFs) stimulated with doxycycline. On the right, detection of Aurora B (red) by immunofluorescence 
in the absence or presence of doxycycline. Anti-centromere antigen (ACA; purple) was used as a control. DAPI (blue) was used to 
stain DNA. Scale bars, 10 µm. 
 
Since Aurora B forms part of the CPC complex we decide to analyse the levels of its partners 
upon overexpression of Aurora B. No changes in the protein levels of its CPC partners INCENP or 
Survivin were observed (Figure 23). 
 
Figure 23. CPC partner protein levels upon Aurora B overexpression. 
Protein levels of the CPC components in Aurora B-overexpressing and 
control MEFs. α-tubulin was used as a loading control. 
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Induction of Aurora B was also evident in non-cycling lymphocytes (Figure 24) and serum-starved 
MEFs (Figure 24) treated with doxycycline, indicating that Aurora B gene induction in this system is 
independent of cell cycle regulation. 
 
a                                                 b 
 
 
c 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Cell cycle independent-overexpression of Aurora B. (a) Aurora B expression is significantly induced in Aurkb+/loxtet 
resting (0h) or concanavalin A + lipopolysaccharide (ConA+LPS)-induced (48 and 96h) splenocytes. PS, Ponceau S. At the 
bottom, Aurora B levels in serum-starved Aurkb+/loxtet; Rosa26M2rtTA/M2rtTA MEFs treated or not with doxycycline for 48h. (b) Edu 
staining in stimulated Aurora B overexpresing lymphocytes. EdU incorporation and DNA content profiles in Aurkb+/loxtet splenocytes 
before or after treatment with concanavalin A + lipopolysaccharide (ConA+LPS).  
 
2.2.2. Impaired proliferation of Aurora B overexpressing MEFs 
Treatment of Aurkb+/tet; Rosa26M2rtTA/M2rtTA MEFs with doxycycline for 5 days resulted in impaired 
proliferation when compared to untreated Aurkb+/tet clones or control Aurkb+/+ fibroblasts (Figure 25). The 
proliferation of untreated Aurkb+/tet MEFs was probably reduced compared to wild-type cells as a 
consequence of the presence of a single functional Aurkb allele in these mutant cells. 
 
 
Figure 25. Growth curve analysis of Aurora B overexpressing MEFs. 
Proliferation of early passage primary MEFs with or without the addition 
of doxycycline. Aurkb+/+ and Aurkb+/tet cells (always in the presence of 
the Rosa26(M2rtTA) allele) were treated with doxycycline or left 
untreated during five days. 
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2.2.3. Mitotic defects caused by Aurora B overexpression  
 
Overexpression of Aurora B did not significantly alter the percentage of cells in mitosis, although 
these mutant cells displayed an increased percentage of prometaphase cells, as observed in Figure 
26a, p=0.02. Mitotic defects, mostly lagging chromosomes and spindles with multiple asters, were 
significantly more abundant in Aurkb+/tet cells treated with doxycycline (14.4 ± 3.7 vs. 4.8 ± 2.7 in untreated 
cells; p=0.0245; Figure 26b and 26c). The percentage of aberrant interphasic cells, including multi-
nucleated cells or cells with micronuclei (Figure 26b and 26c), was also more frequent upon Aurora B 
overexpression (9.8 ± 1.9 vs. 6.3 ± 0.7 in control cultures; p=0.0489). 
 
a                                                                              b 
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Figure 26. Mitotic defects in Aurora B-overexpressing cells. (a) Percentage and distribution of mitotic cells indicating the 
percentage of prometaphase (PM), metaphase (M), anaphase (A) or telophase (T) cells 48 h after the addition of doxycycline. ( 
percentage of cells in PM: 40.34 ± 4.595 vs; 56.26 ± 5.40) (N=400 cells per treatment). (b) Percentage of abnormal mitotic figures 
(left panel) or abnormal interphasic cells (bi, multi and micronucleated cells, right panel) in Aurora B overexpressing cells. (N=50 
cells per treatment) (c) Percentage of mitotic defects (lagging or misaligned chromosomes and aberrant spindles), cytokinesis 
figures and nuclear alterations in interphasic cells in Aurkb+/tet MEFS in the absence or presence of Doxycycline. Representative 
pictures are shown in the upper part of the graphs. DAPI was used to stain DNA. Scale bars, 5 µm. n=400 cells. ns, not 
significant; *, p<0.05; Student’s t-test. 
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2.2.4. Aurora B overexpression leads to an increased duration of mitosis and loading of BubR1 
 
The duration of mitosis was increased in Aurora B-overexpressing MEFs in the absence of these 
microtubule poisons (137.70 ± 9.72 min. vs. 108.2 ± 5.45 in untreated Aurkb+/tet cells; Figure 27). No 
differences on mitotic entry were observed in MEFs overexpressing Aurora B, but the delay in mitotic exit 
as shown by videomicroscopy was indicating defects in chromosome segregation (Figure 27). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27. Increased duration of mitosis in Aurora B-overexpressing MEFs. (a) Schematic representation of the protocol 
used for time-lapse microscopy. Confluent cultures of immortalized Aurkb+/tet; Rosa26M2rtTA/M2rtTA MEFs were infected with 
adenoviruses expressing GFP-tagged histone H2B (H2B-mGFP) following serum deprivation for 48 hours. These cells were 
stimulated with serum and treated or not with doxycycline for 18 hours. Then, the cells were left untreated or exposed to different 
drugs and afterwards, they were monitored by using time-lapse microscopy during an additional 48 h. (b) Duration of mitosis 
(minutes) in untreated or doxycycline-treated cells. The accumulation of mitotic cells (as scored by cell rounding and chromosome 
condensation) in these cultures is shown in the right panel. Representative images of these cultures are shown. Scale bar, 10 μm. 
H2B-mGFP is in green. 
 
The defect on mitosis duration was caused by increased Aurora B as it was prevented by 
treatment of Aurora B overexpressing cells with the Aurora B inhibitor ZM447439 (Figure 28). In addition, 
the defect in the duration of mitosis was rescued by the Mps1 inhibitor, reversine (Figure 28), suggesting 
that mitotic delay in the presence of increased Aurora B levels was caused by SAC activation. 
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Figure 28. Increased duration of mitosis upon Aurora B overexpression is rescued by ZM447439 and reversine 
treatments. The delay in mitotic exit upon Aurora B overexpression was rescued by the Aurora B inhibitor ZM447439. The 
immunoblot shows Aurora B protein levels and phosphorylation of histone H3 (p-H3) in the absence or presence of ZM447439. 
Right panel shows how the delay in mitotic exit upon Aurora B overexpression was rescued by the Mps1 inhibitor reversine. 
 
Aurora B is involved in the error correction mechanism that monitors chromosome attachments to 
the spindle, and its activity generates unattached kinetochores that are sensed by the SAC. 
Overexpression of Aurora B did not alter the response to microtubule poisons such as taxol or nocodazole 
in MEFs, which are known to easily exit from mitosis in the presence of these drugs (Fig. 29).  
 
a                                                   b 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29. Aurora B overexpression results in increased duration of mitosis and increased  loading of BubR1 (a) Duration 
of mitosis (in minutes) in immortal untreated Aurkb+/tet (N=149) or doxycycline induced Aurkb+/tet MEFs (N=164) showing an 
increase in the duration of mitosis when overexpressing Aurora B. No differences were found when exposed to 3.5 μM 
nocodazole or 1 μM taxol. (b) Ratio between BubR1and Mad2 versus anti-centromere antigen (ACA) signal in Aurkb+/tet MEFs 
treated or not with doxycycline. (N=at least 70 centromere signals per group). Representative images of BubR1 and Mad2 (green) 
staining at kinetochores in untreated or doxycycline treated Aurkb+/tet MEFs are also shown. ACA is shown in red and DNA (DAPI) 
in blue. Three different clones from each genotype/condition were analysed. 
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Whereas we found no significant differences in the association of BubR1 or Mad2 to kinetochores 
in the presence of microtubule poisons (data not shown), we observed a significant increase in BubR1 
protein levels at centromeres in unperturbed Aurkb+/tet MEFs overexpressing Aurora B (Fig. 29). Levels of 
centromeric Mad2 were however unaffected in these cells, suggesting a specific limiting role for Aurora B 
in the kinetochore localization of BubR1. 
2.2.5. Mitotic defects upon Aurora B overexpression lead to aneuploidy 
 
In order to assess whether Aurora B overexpression induced chromosomal instability, we performed 
karyotype analyses of metaphase spreads generated from early (passage 2) or late (passage 30) immortal 
MEFs. As shown in Figure 30, overexpression or Aurora B in early passage cells resulted in a broader 
variance in the number of chromosomes after 5 days with doxycycline treatment. In addition, whereas 
control cultures were relatively stable 30 passages later, Aurora B-overexpressing cells showed a 
significantly wider variance in their chromosome numbers (Figure 30), as expected if there were mis-
segregation of chromosomes during cell division. 
 
a 
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Figure 30. Overexpression of Aurora B in vitro leads to aneuploidy (a) Cytogenetic analysis of immortalized MEFs after 
exposure to 5 hours of colcemid. The absolute number of chromosomes per metaphase was grouped in categories at early (iP2) 
or late (iP30) immortal passages. (b) Representative images of aneuploid cells of the indicated genotypes at immortal passage 
(iP) 2 or 30 n represents the number of chromosomes. DNA was visualized with DAPI. Scale bar, 10 µm. ns, not significant; ***, 
p<0.001; Student’s t-test. 
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2.3. Overexpression of Aurora B impairs the DNA damage response 
2.3.1. Aurora B represses the expression of the cell cycle inhibitor p21Cip1 in vitro and in vivo 
 
Aurora B has been shown to inactivate p53 function, lowering expression of its target genes in vitro (Gully 
et al., 2012; Wu et al., 2011). We therefore explored whether p53 or its target genes were affected by 
Aurora B overexpression in cells treated with the topoisomerase II inhibitor Adryamicin. The doxycycline-
dependent induction of Aurora B correlated in these cells with a significant reduction in the level of 
induction of p21Cip1 protein (Figure 31a) and transcripts (Figure 31b). In these assays, the levels of p53 
were not significantly affected by Aurora B overexpression (Figure 31), suggesting that Aurora B affects 
p53 activity rather than its protein levels. Moreover, when measuring DNA damage by H2AX staining in 
cells, a diminished response to this stress could be seen (Figure 31c). 
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b                                                                                c 
 
 
 
 
 
 
 
 
 
 
Figure 31. Overexpression of Aurora B impairs the DNA damage response in vitro. (a) Schematic representation of the DNA 
damage assay performed in Aurkb+/tet; Rosa26M2rtTA/M2rtTA andAurkb+/+; Rosa26M2rtTA/M2rtTA MEFs. Cells were treated with 
doxycycline (Doxy) for 24 h and adryamicin was added for two hours in order to induce p53 signaling. The protein levels of the 
indicated proteins were assessed before and ten hours post-damage induction and the fold change versus non-damaged cells is 
shown on the right histograms. (b) mRNA levels of Aurkb and Cdkn1a (encoding p21Cip1) transcripts in Aurkb+/tet; Rosa26M2rtTA/M2rtTA 
and Aurkb+/+; Rosa26M2rtTA/M2rtTA MEFs at the indicated times (0, 6 and 10 h) after treatment with adryamicin. Gadph transcripts 
were used for normalization. (c) γH2AX levels in cells overexpressing Aurora B were significantly reduced after 10 hours of being 
treated with adryamicin  ns, not significant; *, p< 0.05, **, p<0.01; ***, p<0.001; Student’s t-test. 
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We next analysed whether Aurora B regulates the p53 pathway in vivo by treating Aurkb+/+ and 
Aurkb+/tet mice, in the presence of the Rosa26M2rtTA/M2rtTA alleles, with γ- irradiation (8 Gy). The intensity of 
Aurora B immunostaining increased in the white pulp of the spleen after treatment with doxycycline both in 
irradiated and non-irradiated mice (Figure 32). Whereas overexpression of Aurora B did not significantly 
alter the induction of p53 in these irradiated mice, the percentage of p21Cip1 positive cells was significantly 
reduced in irradiated Aurkb+/tet mice compared to wild-type controls (Figure 32). This effect was 
accompanied by a reduced response to DNA damage, as scored by phosphorylation of H2AX (γH2AX), 
and a significant decrease in the ratio of apoptotic cells after irradiation (Figure 32), suggesting that 
overexpression of Aurora B also impairs the DNA damage response in vivo. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32. Overexpression of Aurora B impairs the DNA damage response in vivo. (b) To induce DNA damage in vivo, 6-8-
week-old Aurkb+/+; Rosa26M2rtTA/M2rtTA mice and Aurkb+/tet; Rosa26M2rtTA/M2rtTA mice were treated for fifteen days with doxycycline 
and were subjected to irradiaton (IR; 8 Gy γ-irradiation). The level of the indicated proteins was tested by immunohistochemistry in 
the spleen 24 h later. AC3, active caspase 3. Scale bar, 50 μm. ns,not significant; *, p<0.05; **, p<0.01; ***, p<0.001; Student’s t-
test. 
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2.4. Aurora B overexpressing mice are tumour prone and aneuploid 
2.4.1. Increase tumour incidence in Aurora B overexpressing mice  
 
To monitor long-term effects of Aurora B overexpression in vivo, Rosa26M2rtTA/M2rtTA mice harboring the 
mutant Aurkb(tet) or Aurkb(loxtet) alleles were treated with doxycycline in the drinking water for 20 
months. We first confirmed the in vivo induction of Aurora B by analyzing mRNA (Figure 33a) and protein 
levels (Figure 33b) in several proliferative and non-proliferative tissues of Aurora B overexpressing mice. 
Although both mutant alleles resulted in Aurora B overexpression, the levels of Aurora B were higher in 
Aurkb+/tet tissues when compared to the corresponding Aurkb+/loxtet samples. 
 
a                                                                        
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Figure 33. In vivo characterization of Aurora B overexpressing mice. (a) Expression of Aurora B transcripts in the indicated 
tissues from Rosa26M2rtTA/M2rtTA mice harboring the Aurkb(loxtet) and Aurkb(tet) alleles after treatment with doxycycline for two 
weeks. mRNA levels were normalized versus the expression of Gadph mRNA. (b) Immunohistochemical detection of Aurora B in 
the indicated tissues and genotypes. Scale bar, 50 μm. 
 
Whereas for Mad2 and Bub1, the relationship between them and tumour initiation has been 
precisely explored, whether Aurora B has a role in aneuploidy induction and tumour development still 
remains unclear. Some studies have related Aurora B deregulation to aneuploidy and cancer (Terada, 
1998; Ota, 2002; Nguyen, 2009) and its oncogenic potential has been measured together with Ras  
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oncogene (Kanda et al; 2005), but the tumourigenesis potential of Aurora B and the molecular and cellular 
consequences of Aurora B overexpression have not been proven by itself. 
Importantly, Aurkb+/tet and Aurkb+/loxtet mice were characterized by a high incidence of tumour 
development during ageing. Whereas spontaneous tumours were detected in 14.28% of control mice, 
58.3% of the Aurkb+/loxtet mice and more than 90% Aurkb+/tet mice had at least one tumour (p=0.0006 
Aurkb+/tet vs. wild-type mice; Figure 34a). Furthermore, 60% of Aurkb+/tet mice and 25% of Aurkb+/loxtet mice 
were simultaneously affected with more than one tumour type (Figure 34a). Histological analysis of both 
Aurkb+/tet and Aurkb+/loxtet mice showed a wide spectrum of tumours, with spleen lymphomas being the 
most common neoplasia (25% and 93.3% of Aurkb+/loxtet and Aurkb+/tet mice, respectively; Figure 34b). 
 
a  
                                                            b 
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Figure 34. Aurora B overexpressing mice develop spontaneous tumours. (a) Spontaneous tumour incidence (one tumour or 
more than 1 tumour per mouse) (b) Type of neoplasias found in Aurora B-overexpressing mice (percentage of incidence is 
represented). (c) Hematoxylin and eosin (H&E) staining of the indicated tumours found in Aurkb+/tet; Rosa26M2rtTA/M2rtTA mice. i,ii, 
spleen lymphoma; iii, histiocytic sarcoma; iv, lung adenoma. ns, not significant; *, p<0.05; ***, p<0.001; Chi-Square test.  Scale 
bar, 100 μm: 
 
Aurora B overexpression in Aurkb+/tet mice also resulted in sarcomas (25%), alveolar type II cell 
adenomas in the lung (13.33%), liver hemangiomas (20%) as well as other more infrequent tumours and 
non-tumoural lesions (Figure 34).The lymphomas found in Aurora B overexpressing mice were follicular B 
cell subtype (Pax5-positive; Figure 35) characterized by enlarged spleen follicles populated by a mixture of 
cells including centrocytes, centroblasts and Cd3+ T-cells (Figures 34 and 35).  
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Figure 35. Characterization of spleen 
lymphomas found in Aurora B 
overexpressed mice. Representative 
pictures of Pax5 and CD3 staining in 
tumour samples from the spleen, liver 
and pancreas of Aurkb+/tet; 
Rosa26M2rtTA/M2rtTA mice. Scale bar, 50 
µm.  
 
 
 
 
Aurkb+/tet lymphomas presented a higher degree of aggressiveness as shown by infiltrations in 
the lung, liver, kidney and bone marrow, where these tumours preferentially metastasized (Figure 36).  
 
 
 
 
 
 
 
Figure 36. Metastatic tumours in Aurora B overexpressing mice. H& E images of lymphoma metastasis in the lung, liver, 
kidney and bone marrow of Aurkb+/tet; Rosa26M2rtTA/M2rTTA mice. Scale bar, 200 µm. 
 
2.4.2. Aneuploidy in Aurora B overexpressing mice 
 
We next asked whether overexpression of Aurora B caused aneuploidy in peripheral blood lymphocytes of 
mutant mice. We scored interphasic nuclei by FISH, using probes against chromosomes 8 and 11. Age-
dependent accumulation of aneuploidy in lymphocytes was observed in both genotypes although Aurkb+/tet 
animals contained significantly higher percentage of aneuploid cells (Figure 37). The percentage of 
aneuploidy, calculated as the deviation from the mode, was 0.28% in 4-month old Aurkb+/+ mice and 3.04% 
in Aurkb+/tet littermates (p=0.0021). At 20 months of age, these numbers increased to 3.00% in Aurkb+/+ 
and 7.66% in Aurkb+/tet mice (p= 0.0033; Figure 37). Levels of aneuploidy were not significantly different 
when analyzing untreated Aurkb+/+, Aurkb+/loxtet or Aurkb+/tet mice aged for 20 months. 
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Figure 37. In vivo overexpression of Aurora B induces aneuploidy. (a) Levels of aneuploid cells in Aurkb+/+; 
Rosa26M2rtTA/M2rtTA and Aurkb+/tet;Rosa26M2rtTA/M2rtTA mice after 4 or 20 months in the presence of doxycycline. Aneuploidy 
(deviation from the mode) was scored using FISH for two different chromosomes in lymphocytes from 4 and 20-month-old animals 
(at least n=100 from each of four animals per genotype and time point). Each column represents one animal of the indicated 
genotypes. **,p<0.01; ***, p<0.001; Student’s t-test. (b) Representative images of interphasic FISH analysis using probes for 
chromosomes 8 (red) and 11 (green).Dot lines represent aneuploid cells. Scale bar indicates 20 μm. 
 
 
2.5. Aurora B overexpressing tumours display increased aneuploidy and reduced  p21 Cip1 
levels 
2.5.1. Increased aneuploid levels in Aurora B overexpressing tumours 
Spleen sections from tumour-bearing and healthy 20-month-old Aurkb+/tet and wild-type mice were 
hybridized with FISH probes against chromosomes 8 and 11. The percentage of aneuploid cells in non-
metastatic (“initial”) or advanced, metastatic Aurkb+/tet tumours was significantly higher than in non-
tumoural (NT) spleen cells from age-matched wild-type animals (Figure 38a). Aneuploidy also increased in 
the spontaneous tumours observed in Aurkb+/+ mice (8% of aneuploid cells in spleen tumours versus 4% 
in NT spleens), although it never reached the levels found in initial (10.9%) or advanced (14.8%) Aurkb+/tet 
tumours (Figure 38).  
 
 
Figure 38. Aurora B overexpressing mice develop spontaneous 
tumours with aneuploid cells. Percentage of aneuploid cells in non 
tumoural (NT) spleens, or spleens with initial or fully developed tumours 
(T) from the indicated genotypes. Initial tumour refers to small, non-
metastatic tumours. FISH was performed for chromosomes 8 (red) and 
11 (green) on spleen sections from 80-week old mice.Dot lines respresent 
aneuploid cells. Each column represents one animal of the indicated 
genotypes. Representative images are shown at the bottom. Scale bar 
indicates 20 μm. At least 100 cells were counted per condition.  
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The increase in total aneuploidy reflected both an increase in both near-diploid and near-
tetraploid aneuploid cells within spleen lymphomas (Figure 39). Similar results were found in lung tumours, 
the most prominent epithelial-originated tumour in Aurkb+/tet mice. Together these data suggest that 
Aurora B-overexpression leads to chromosomal instability in vivo, which may precede to overt 
transformation. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39. Aneuploidy levels in spleens from Aurora B overexpressed mice. Percent of near-tetraploid cells and aneuploid 
cells (excluding those scored as near-tetraploid) determined by chromosome FISH hybridization in non-tumoural (NT) or tumoural 
[(T), either initial (Init-T) or fully developed tumours (T)] spleen samples from AurkB+/+; Rosa26M2rtTA/M2rtTA and AurkB+/tet; 
Rosa26M2rtTA/M2rtTA mice. Each column represents one animal of the indicated genotypes. 
 
2.5.2. Reduced p53 and p21 levels in Aurora B overexpressing tumours 
 
By monitoring the doxycycline treated animals we observed that the Aurora B overexpresing mice are 
more prone to develop spontaneous lymphomas and histiocytic sarcomas and present a shortening life 
span versus the wild type mice. Moreover, since Aurora B can modulate p21Cip1 levels (Figure 31), we also 
analysed p53 and p21Cip1 levels in spleen tumours. p53 protein levels were significantly reduced in 
Aurkb+/tet tumours in comparison to tumoural or non-tumoural spleen samples from Aurkb+/+ mice (Figure 
40). Similarly, a significant decrease in p21Cip1 levels was also found in spleen tumours from Aurkb+/tet mice 
compared with similar tumours from Aurkb+/+ animals (Figure 41a). p21Cip1 was almost absent in metastatic 
Aurkb+/tet tumours, in line with their aggressive phenotype.  
 
 
 
 
 
 
 
 
Figure 40. p53 levels in non-tumoural and tumoural spleen samples from overexpressing Aurora B mice. Immunodetection 
of p53 in non-tumoural (NT) or tumoural (T; either initial or fully developed) spleen samples from AurkB+/+; Rosa26M2rtTA/M2rtTA and 
AurkB+/tet; Rosa26M2rtTA/M2rtTA mice. Scale bar, 80 µm. The quantification of the percentage of p53 positive cells is shown in the 
histogram. *, p<0.05; ***, p<0.001; Student’s t-test. 
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To test whether these observations may also apply to human lymphoblastic leukaemias, we 
compared AURKB and CDKN1A (the human gene encoding p21Cip1) mRNA levels in B acute 
lymphoblastic leukaemia (B-ALL) samples (Harvey et al., 2010; Kang et al., 2010). As represented in 
Figure 41b, the levels of expression of these transcripts displayed a significant inverse correlation in which 
p21Cip1 expression was constantly low in tumours expressing high levels of Aurora B. All together, these 
data suggest that Aurora B overexpression triggers tumour development in association with both 
increased aneuploidy and defective p21Cip1 function. 
a                                                                     b 
 
 
 
 
 
 
 
 
 
 
 
Figure 41. Aurora B overexpression correlates with p21Cip1 repression. (a) p21Cip1 levels in nontumoural (NT) and tumoural 
(T) spleen samples from Aurkb+/+ mice in comparison to initial and fully developed tumours from Aurkb+/tet mice. Scale bar, 80 μm. 
*, p<0.05; ***p<0.001; Student’s t-test. (b) Inverse correlation between AURKB and CDKN1A mRNA levels in 207 samples of 
human B acute lymphoblastic leukaemia (B-ALL). Pearson correlation; p<0.05. The expression of Aurkb mRNAs in human 
tumours was analysed using the Oncomine database (Compendia Bioscience). The number of analyses with significant (P < 
0.0001, Student t test; fold change, >2; gene rank threshold, top 10%) overexpression of each gene is indicated. 
 
2.6. Aurora B overexpression results in a metabolic defect in adult mice 
Interestingly, since 7 months of doxycycline treatment, we observed in Aurkb+/tet mice an increase in their 
body weight accompanied by huge liver, spleen and pancreas steatosis and big visceral fat vacuoles 
surrounded by lymphocytes (Figure 42). Furthermore, a mix of brown adipose tissue and white adipose 
tissue (BAT/WAT) was observed in particular areas of the BAT (Figure 42). This phenotype led us to think 
on an Aurora B role in metabolism. In fact, it has been previously describe that Aurora B has an important 
role in the transcription initiation of T3-responsive genes by interaction with tyroid receptor (T3) in a ligand 
dependent manner in cells that do not proliferate (Tardáguila et al., 2011). 
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Figure 42. Metabolic alterations found in Aurora B overexpressing mice. (a) Hematoxylin and eosin (H&E) staining of the 
indicated tissues from Aurkb+/tet; Rosa26M2rtTA/M2rtTA mice. i, mixed BAT and WAT; ii, liver steatosis; iii and iv, fat vacuoles. Scale 
bar, 100 μm.(b) Aurkb+/loxtet treated with doxycycline showed a significant gain of weight when compared with control mice (**, p< 
0,01; n=3) (c) Aurkb+/tet mice were characterized by different pathologies, being steatosis and mixed BAT& WAT the most 
prominent. 
 
Then, we decided to analyse the cause of this surprising phenotype by taking advantage of a 
metabolic cage (Oxylet machine). Aurkb+/tet mice and Aurkb+/+ mice were subjected to that analyse after 
1.5 months after doxycycline treatment showing altered calorimetry and activity. By analyzing the 
respiratory quotient (RQ) value, an indirect form of calorimetry, which is the ratio C02 eliminated/ O2 
consumed, a reduced metabolic flexibility could be observed. And from these parameters we studied the 
energy expenditure (EE), which refers to the amount of energy (calories) used by the body, a reduced 
value was obtained in the Aurora B overexpressing mice. Regarding the intake, the water intake was 
equal in Aurora B overexpressed and wild-type mice whereas there was a tendency in the food intake to 
be higher in the transgenic mice as well as in their activity, though none of these parameters was 
statistically significant (Figure 43). Since a tendency in several of these parameters exits, we will further 
follow the analysis of the Auorora B overexpressing mice until 6 months of doxycycline treatment, time at 
which the apparent metabolic phenotype could be observed. 
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Figure 43. Metabolic parameters analysed in Aurora B overexpressing mice. (a) RQ value (Vo2/Vco2) in wild- type and 
Aurora B overexpressing mice during day and night (after 1.5 months of doxycycline treatment). (b) Energy expenditure 
(calculated from the V02 and VCO2 using the Weir Equation;p=0.094. (c) Total Food and drink intake and total Activity in wild-
type and transgenic mice. Night hours are highlighted in grey. ANCOVA’s test; n.s. 
 
3. Differential role of Aurora C and B in pluripotency induction 
The use of pluripotent cells to understand human disease is crucial nowadays. Induced pluripotent cells 
(iPSCs) are manifested towards an ‘open’ and dynamic chromatin state that enables their functional 
plasticity, which is thought to be ensured by epigenetic marks transmitted through cell division. We 
previously observed that Aurora C is specifically expressed in early embryos/embryonic stem cells, 
whereas at the blastocyst stage this kinase is replaced by Aurora B (except germ cells; (Fernández-
Miranda et al., 2011). Moreover, the study of Sabbattini P. and collaborators (Sabbattini et al., 2007) saw 
that Aurora B epigenetically marks silent chromatin during cell differentiation. Taking into account these 
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data we hypothesize that Aurora C may have opposed regulatory functions to Aurora B, so that during 
reprogramming to pluripotency, Aurora C could enhance access to chromatin by epigenetic modifications 
(Figure 44). Since no experiments to date have addressed what is the endogenous function of Aurora C in 
any somatic cell, we aim to discover how this protein works and the best way to analyse this objective is in 
embryonic stem cells (ESs) and induced pluripotent cells (iPCs).  
 
 
 
 
 
 
 
 
 
Figure 44. Hypothesis on the role of Aurora C in pluripotency. Aurora B levels increase while embryo development 
progresses, whereas Aurora C levels are high till the morula stage where it functions as the CPC kinase and decrease during 
subsequent embryo divisions. This data together with the fact that Aurora B seems to be implicated in differentiation processes by 
epigenetically silencing chromatin domains led us think that Aurora C may have a role in mediating stemness function. 
3.1. Aurora C is not expressed in MEFs but it is activated during reprogramming to iPCs 
 
We focused on studying the functional differences between these two important kinases, Aurora B and C. 
First, we corroborated that both iPSCs and ES express Aurora C at the transcript level (Figure 45a). Since 
no good antibody for Aurora C is available its protein levels could not be analysed. As expected, the 
protein levels of Aurora B and A were much higher in ESs and iPCs than in MEFs as it was for the 
phosphorylation of histone 3 (Figure 45b).  
  By taking advantage of doxycycline inducible 4F MEFs (Abad et al., 2013), carrying the 
transcriptional activator (rtTA) within the ubiquitously-expressed Rosa26 locus and a single copy of a 
lentiviral doxycycline-inducible polycistronic cassette encoding the four murine factors Oct4, Sox2, Klf4and 
c-Myc, the endogenous levels of Aurora B and C were studied during the reprogramming of murine cells to 
iPCs. Endogenous Aurora C expression was clearly increased during reprogramming at the same time 
that Nanog increased (day 6 after the initiation of the reprogramming process), whereas Aurora B 
expression was maintained equal throughout the reprogramming to iPCs (Figure 45c). 
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Figure 45. Aurora C is expressed in iPCs and ES cells and is activated during the reprogramming process. (a) Trancript 
levels of Aurora B and C in ESs, iPCs and MEFs. Cyclin B1 was used as an internal control of cell division as it was vinculin as a 
marker characteristic of fibroblasts. (b) Inmunoblot analysis in MEFs, iPCs and ES cells showing an upregulation of Aurora 
kinases A and B and pH3 in ESCs and iPCs versus MEFs. Nanog was used as a control of pluripotency and vinculin as being 
expressed in cell to cell adhesion (MEFs) and cell to matrix (ESCs mainly). (c) RT-qPCR analysis of Aurora kinases B and C 
mRNA levels were measured by q-PCR during the reprogramming process in doxycycline inducible OSKM MEFs which shows no 
differences in the levels of Aurora B but an increase in the levels of Aurora C starting at day 6 of the reprogramming process. 
Nanog was used as a control of pluripotency and β-actin as a loading control. On the right, representative pictures of primary 
mouse embryonic fibroblasts (MEFs) during reprogramming to pluripotent cells, showing pluripotent colonies Rosa-rtTTA; lenti-4F 
MEFs were used to induce pluripotency conditionally by adding 1µg/ ml doxycycline to cells media. iPS RNA extract was used as 
control of the experiment. 
 
3.2. Overexpression of Aurora C enhances the efficiency of reprogramming to iPCs 
 
Then, we focus our study on analyzing the reprogramming efficiency upon Aurora B/C 
overexpression/depletion. We used murine embryonic fibroblasts that were transfected one day before 
pluripotency induction with plasmids expressing GFP (empty vector,EV) or GFP fusion proteins containing 
wild-type Aurora C wt or Aurora B wt, or kinase dead (KD) mutant forms of these proteins, Aurora C-KD, 
Aurora B-KD. These primary cells were reprogrammed and stained for Alkaline Phosphatase at day 0, 3, 
6, 9, 12 and 15 in order to count the number of stem cell colonies.  
We clearly visualized a highly significant enhancement (3.67 times fold change) of the 
reprogramming efficiency (number of ES colonies) upon Aurora C overexpression when compared to 
Aurora B or empty vector conditions. And as expected in the KD forms of both proteins, the number of 
colonies was significantly reduced (Figure 46). We can conclude that Aurora C and not Aurora B seem to 
be necessary for maintenance of pluripotency. 
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Figure 46. AurkC enhances reprogramming efficiency. Number of Alkaline Phosphatase stained colonies at days 9, 12 and 
15. Embryonic fibroblasts were transfected one day before pluripotency induction with plasmids expressing GFP (empty vector, 
EV) or GFP fusion proteins containing wild-type Aurora B (AurkB wt), Aurora C (AurkC wt) or kinase dead mutant forms of these 
proteins (AurkB KD and AurkC KD). A huge increase in this process is observed upon Aurora C overexpression Graph shows the 
number of stem positive colonies at day 15 of the reprogramming process. Fold change of Aurora C versus EV is shown. On the 
right, pictures showing colonies along the reprogramming process from day 0 to day 15. Alkaline Phosphatase staining (red) 
during reprogramming of Rosa-rtTTA; lenti-4F MEFs. 
 
In order to know whether the effects on reprogramming are due to an increase activation of the 
cell cycle division, we decided to analyse the effects of Aurora C overexpression in MEFs proliferation. 
Since no differences were found in terms of cell growth, the observed effect on reprogramming efficiency 
must be due to a non-mitotic function of Aurora C. 
3.3. Active epigenetics marks upon Aurora C overexpression 
 
The reprogramming process is accompanied by several changes in the epigenome mostly on 
pluripotency-related or developmentally regulated gene promoters. These changes are critical to allow a 
permissive transcriptional program and an open and decondensed chromatin state, characteristic of 
pluripotent cells (Bernstein et al; 2006). 
Since we observed that by overexpressing Aurora C during reprogramming the number of 
colonies increased, we aimed to go further and analyse how the epigenome was changing during 
reprogramming upon Aurora B/C induction. We therefore analysed the epigenetic modifications in the 
above mentioned Aurora B/C overexpressed/deficient murine cells during the first 6 days of 
reprogramming. This is due to the fact that although the transition from a somatic like chromatin structure 
to an ESC like structure occurs at day 7 or later, chromatin reorganization occurs early preceding nanog 
expression during reprogramming (day 6 or earlier) (Mattout A et al; 2011). We tested the status of 
acetylation and methylation marks that correlate with transcriptional activity and the marks presenting the 
highest degree of correlation with pluripotent state are the acetylation of lysine 9 in histone 3 (H3K9Ac) 
and the trimethylation of lysine 4 in histone 3 (H3K4me3). These epigenetic marks for transcription 
activation were upregulated in Aurora C overexpressed cells (Figure 47). 
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Figure 47. Aurora C epigenetic modifications. Inmunoblot of epigenetic marks at day 0, 3 and 6 of the reprogramming process. 
Embryonic fibroblasts were transfected one day before pluripotency induction with plasmids expressing GFP (empty vector, EV) or 
GFP fusion proteins containing wild-type Aurora B (AurkB wt), Aurora C (AurkC wt) or kinase dead mutant forms of these proteins 
(AurkB KD and AurkC KD). The status of H3K9Ac and H3K4me3 histone marks, which correlate with activation of the 
transcriptional activity was tested.  
 
Overall these data show a differential role of Aurora B and C proteins in pluripotency induction, a 
question that deserves further investigation in future projects. 
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Discussion 
 
In this work we have investigated the physiological relevance of deregulating the cell cycle kinase Aurora 
B, which is crucial for a proper segregation of chromosomes during mitosis. Strikingly, we found that its in 
vivo depletion leads to a premature ageing phenotype characterized by an upregulation of apoptosis, 
aneuploidy and lack of stem cell renewal. This indicates that Aurora B is necessary for tissue 
regeneration. On the other hand, long-term overexpression of Aurora B results in the development of 
multiple tumours, accompanied by an increase in aneuploidy and impaired induction of the p53 target 
p21Cip1, phenotype that goes along an altered metabolism. Thus, suggesting that Aurora B overexpression 
may favor both aneuploidy and p21Cip1 down-regulation during tumour development and that Aurora B has 
functions outside mitosis. Finally, we have found that Aurora C and not Aurora B seems to be required for 
stemness condition.  
 
1. Aurora B biological function. Consequences of Aurora B deregulation  
 
Aurora B, the catalytic component of the Chromosomal Passenger Complex (CPC), is an essential kinase 
in the error correction mechanism that ensures proper chromosome segregation when cells divide 
(Ditchfield et al., 2003; Lampson and Cheeseman, 2011). It has been previously described that Aurora B 
deregulation (exogenously downregulating/overexpressing the protein) contributes to chromosomal 
instability and leads to mitotic defects (Hauf et al., 2003) (Terada et al., 1998) (Ota et al., 2002). In this 
work, we took advantage of genetically modified mouse models for Aurora B depletion/overexpression 
which allowed us to faithfully analyse the physiological consequences of the protein deregulation in vivo.  
 
1.1. Effect of Aurora B depletion in adult mice 
 
Aurora B, due to its critical roles in the cell cycle, it is required for proper cellular proliferation in cultured 
cells (Hauf et al., 2003; Nguyen et al., 2009) (Fant et al., 2010; Tatsuka et al., 1998), and its genetic 
inactivation results in embryonic lethality after implantation (Fernandez-Miranda et al., 2011; Fernández-
Miranda et al., 2011; Ye et al., 2009). Due to the use of Aurora B inhibitors as antitumoural agents 
(Ditchfield et al., 2003; Harrington et al., 2004; Hauf et al., 2003), we decided to analyse the 
consequences of its depletion in adult mammals in order to discriminate the specific effects of the 
inhibition of Aurora B associated with the use of these inhibitors. 
Using a conditional knock-out model we show here that Aurora B is critical for cell proliferation in 
adult mammals, a feature that has been critical for their consideration as a putative cancer target. Lack of 
cell proliferation together with increased apoptosis made Aurora B depleted mice present decreased 
survival. Our results suggest that lack of Aurora B results in defective chromosome segregation that leads 
to the generation of aneuploid cells together with an induction of p53 and its main target gene p21Cip1  
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(Figures 13 and 14). Interestingly, aneuploid cells are characterized by the induction of DNA damage 
response as a consequence of induction of replicative stress (Storchová et al., 2006). The cause of the 
decreased survival was a clear ageing phenotype together with a loss of body weight, similar to loss of 
function models for other mitotic regulators previously described (Baker et al., 2004; Pérez de Castro et 
al., 2013).  
These data indicate that the observed phenotype upon Aurora B depletion is due to an impaired 
proliferation caused by mitotic abnormalities and increased apoptosis and p53 response which together 
with les regenerative capacity of stem cells generates premature-ageing mice (Figure 15). The 
upregulation of p53 we observed could be due to an increased stability of the protein. In addition, we have 
observed an intriguing reduction of stem cell renewal (Figure 18), an observation that could be used to 
induce tumour arrest by inhibiting the protein in some specific tissue areas.  
Two cellular mechanisms can contribute to chemo/radioresistance: inhibition of apoptotic cell 
death pathways and induction of autophagy, a cell survival response. The phenotype observed in the 
Aurora B depleted mice was similar to AurkaΔ/Δ mice (Pérez de Castro et al., 2013). Both models display a 
premature ageing phenotype, together with less regenerative capacity of tissues and an increased p53 
response. However, unlike the senescence induced in AurkaΔ/Δ mice, Aurora B depleted mice presented 
increased apoptotic cells which make the inhibition of Aurora B an important tool for the clinic. This data 
has relevance in cancer therapies since the inhibition of Aurora B could sensitize tumours to anticancer 
agents that are more selective to cancer cells with high levels of p53/p21Cip1. Since autophagy plays a role 
in chemotherapy and radiotherapy resistance, analyse this pathway in the AurkbΔ/Δ mice would be of 
interest, because if autophagy is inhibited, the resistance mechanisms to Aurora B inhibitors are much 
less feasible. 
 
1.2. Aurora B overexpression : Comparison to other mouse models of mitotic regulators 
 
Due to the important role of Aurora B in mitosis and its correlation to tumour grade, it is highly 
important to know the effect of Aurora B in mammals in terms of tumour development. Here, with the aim 
of studying the relationship between Aurora B upregulation and cancer an Aurora B ovexpression model 
was generated. This model was generated also to analyse whether chromosomal instability is the 
mechanism that drives cancer upon Aurora B overexpression. We have taken advantage of a robust 
system to modulate the expression of endogenous genes in mammals by using the promoter “hijack” 
strategy previously used to modulate gene expression in chicken DT40 cells (Fant et al., 2010; Samejima 
et al., 2008). Replacement of endogenous promoter regions by tetracycline-responsive elements results in 
a robust control of endogenous gene expression both in vitro and in vivo eliminating the need to express 
exogenous genes (Figure 20 and 21). In this way, Aurora B is upregulated ubiquitously in the mice by the 
addition of tetracycline while Aurora B coding region remains intact. 
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It is known by extensive studies in murine models that reduced expression of mitotic components, 
as well as its overactivation, is associated with an increase of spontaneous cancer. Bub1 hypomorphic 
mice develop lymphomas, lung and liver tumours with high incidence (Jeganathan et al., 2007), whereas 
heterozygous animals for Mad2 develop benign lung tumours with long latencies (Dobles  
et al., 2000). Likewise, CenpE heterozygous animals evolve benign lung tumours but also splenic 
lymphomas (Weaver and Cleveland, 2006; Weaver et al., 2007) and heterozygous BubR1 mice are prone  
to develop colon adenocarcinomas when carcinogenesis is induced (Dai et al., 2004) or in a background 
of an APC (min) mutation (Rao et al., 2005). Whereas mutations that inactivate mitotic genes are rarely 
observed in human cancers, overactivation of these genes is a much more frequent event than their loss 
or partial loss of function. In this way, the mitotic checkpoint components Mad2, Bub1 or the Aurora B 
substrate Hec1/Ndc80 overexpression are known to drive aneuploidy and to initiate tumourigenesis in 
inducible murine models (Sotillo et al., 2007) (Diaz-Rodríguez et al., 2008) (Ricke et al., 2011). These 
overexpression models result in aneuploidies in vitro and in a increase tumour incidence in vivo. However, 
other events that contribute to tumour formation such as gain of oncogenes or loss of tumour suppressors 
can not be discarded. 
The mouse model described here confirms the effect of Aurora B overexpression in the 
generation of misaligned chromosomes and in triggering a SAC-dependent response (Figure 27 and 29) 
as recently reported in yeast cells when overexpressing Aurora B in combination with INCENP. In that 
study the overexpression of both proteins generates defects in chromosome segregation produced by the 
continuous disruption of kinetochore-microtubule attachments. This disruption collapses the mitotic 
spindle, thus promoting genomic instability (Munoz-Barrera and Monje-Casas, 2014). Aurora B may be 
involved in the localization of Mad2 and BubR1, proteins that recognize correct chromosome attachment 
to spindle microtubules since loss of Aurora B lowers the concentration of Mad2 and BubR1 at the 
kinetochores (Ditchfield et al, 2003). Here, the mitotic defects caused by Aurora B overexpression, mainly 
lagging and misaligned chromosomes, are accompanied by increased levels of BubR1 at the kinetochores 
(Figure 26), in line with previous work showing that Aurora B participates in the recruitment of BubR1, but 
not Mad2 (Ye et al., 2009).  
Aurora B is essential for SAC activation in response to taxol, but its requirement for the SAC in 
the absence of microtubules is still a matter of debate given the partial effects found in multiple assays and 
the limited efficiency and specificity of chemical inhibitors. So that, our results are consistent with the 
concept that Aurora B regulates the SAC at least in part by targeting BubR1 to the kinetochores, function 
that has been previously postulated on entry into mitosis (Ditchfield et al., 2003).  
Moreover, Aurora B overexpressing cells display an increase in the number of multiaster (Figure 
26), which imply that Aurora B deregulation provokes the formation of multiple poles/MTOCs thus 
promoting chromosomes misalignments. These alterations produce with time CIN, as previously 
postulated (Nguyen et al., 2009; Ota et al., 2002; Terada et al., 1998). CIN and SAC hyperactivation 
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induce an increase in the length of mitosis, consistent with a reduction in the proliferation capacity of cells 
(Figure 25) as it has been previously shown for other mitotic regulators (Zhang et al., 2004)(Sotillo et al., 
2007). The observed effect on SAC upon Aurora B overexpression seems to be similar to the effect found 
upon its depletion (Girdler et al., 2006) in which an increase in DOM is seen upon Aurora B inhibition. 
Taken together, our results are consistent with previous models of aneuploidy in which CIN has an in vitro 
negative effect on cellular viability (Sotillo et al., 2007; Torres et al., 2008). 
 
2. Is Aurora B causally associated to tumourigenesis?   
 
Genomic studies have suggested the presence of an expression signature in which the 
overexpression of about 70 genes is associated with chromosomal instability (CIN) in cancer (Carter et al., 
2006). This signature is enriched in regulators of the cell division machinery. The genes implicated in all of 
these processes are known to be misregulated in tumours and it is now well accepted that both increases 
and decreases in the expression of mitotic genes can induce CIN. Within all of them, some genes that are 
involved in the regulation of chromosome segregation such a Aurora B, Mad2 or Bub1, correlate with 
tumour grade and prognosis in a variety of human tumours (Shigeishi et al., 2001; Tanaka et al., 2008). 
An unresolved question in cancer is whether tumour-associated overexpression of proteins is just 
a consequence of cell transformation or whether it indicates a causal role for the protein. This question is 
especially difficult to address in the case of cell cycle regulators, given the general increase in cell 
proliferation rates observed in tumour cells. Defects in the cell cycle machinery are commonly linked to 
cancer, either by promoting unscheduled proliferation, or by allowing the introduction of genomic 
abnormalities in the daughter cells. One of the hypotheses is that aneuploidy drives tumourigenesis by a 
mechanism in which oncogenes are gained or tumour suppressor genes are lost (Lengauer et al., 1998). 
However, at the moment, the link between aneuploidy induction and tumour development still remains 
unclear. Aurora B is overexpressed in many tumour types and a correlation between its levels and tumour 
grade/poor clinical prognosis has been proposed (Chieffi et al., 2004; Gibson et al., 2008; Hegyi et al., 
2012; Smith et al., 2005; Sorrentino et al., 2005; Tanaka et al., 2008). Previous cellular studies indicate 
that sustained overexpression of Aurora B in murine epithelial cells induces tetraploidy and chromosomal 
instability, increasing the oncogenic potential of cultured cells (Ota et al., 2002) (Fant et al., 2010; Sotillo et 
al., 2007) but the in vivo tumourigenesis potential of Aurora B overexpression by itself has not been 
proven so far.  
Does Aurora B has a causal role in tumourigenesis by aneuploidy induction? Though correlations 
between Aurora B level of expression and the severity of tumours have been described in humans (Table 
1), there is no a genetic study of causal connection between Aurora B, aneuploidy and cancer. Our ability 
to chronically induce Aurora B overexpression in the mouse allowed us to analyse the consequences of 
the resulting mitotic defects during ageing due to Aurora B overexpression. Overexpression of Aurora B in 
vivo resulted in a significant increase in aneuploidy accompanied by a dramatic susceptibility to 
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spontaneous tumours (Figures 34 and 37). Thanks to this study we can now state that Aurora B, which is 
overexpressed in many human tumours (Table 1) is causally associated with tumour development. The 
aneuploid levels in the Aurora B overexpressing mice at 4 months of induction was low (3% of cells were 
aneuploid) as found in the hyperactivated model for Mad2 (5.7% of aneuploidy) but both predisposed to 
the appearance of a wide range of lethal tumours. However, CENP-E defective mice present 35% of 
aneuploidy in their blood cells, though this alteration induces only 10% of tumour appearance as in the 
case of Bub1-overexpressing mice that present 30% of aneuploidy in lymphocytes after 5 months of 
induction whereas splenic lymphomas only present 12% of aneuploid cells. Interestingly, an excess of CIN 
is known to act in a tumour suppressive manner (Rao et al.; 2005; Weaver et al.; 2007) because cells are 
not able to tolerate high levels of aneuploidy and die.  
Whereas Aurora B-overexpressing tumours presented 15% of aneuploidy (Figure 38), similar to 
CENP-E tumoural samples (17% of aneuploid cells), other tumours produced upon overexpression of 
mitotic regulators such as Hec1 have around 40% of aneuploid cells (Schvartzman et al., 2010), indicating 
that the tumourigenesis obtain upon Aurora B overexpression was not only due to aneuploidy induction. 
Most probably, other factors, such as tumour suppressors are implicated as previously observed in other 
mitotic models (Schvartzman et al., 2011). 
In our model, peripheral blood cells as well as splenocytes display higher frequency of cells with 
less than a diploid complement of chromosomes than those with more than 2n. There was a bias towards 
chromosome loss although chromosome gains were also frequently observed. This fact may occur 
because cells that have acquired a rare transformative karyotype through multiple chromosome 
missegregations are likely to lose that karyotype in the next round of cell division. 
Recently, it has been hypothesized that Aurora B is a critical target through which overexpressed 
Bub1 drives aneuploidization and tumourigenesis (Ricke et al., 2011). There are striking similarities 
between Aurora B and Bub1 overexpression models. Lagging and chromosome misalignments that are 
seen upon Aurora B overexpression result in aneuploidy as seen in Bub1 overexpressing cells. 
Nevertheless, no differences in the DOM neither on mitotic checkpoint signaling were observed upon 
Bub1 overexpression. Moreover, Bub1 overexpression in MEFs leads to premature sister chromatid 
separation (PMCS) and cells are able to maintain an arrest in response to nocodazole or taxol, similar to 
wild type cells. These differences with Aurora B overexpression model may be related to the levels of 
mitotic checkpoint hyperactivation or to separate effects of both proteins on regulating the checkpoint. 
Regarding the tumour spectrum found in Bub1 model, this was similar to the Aurora B overexpression 
model: lymphomas, sarcomas and lipogranulomas were mainly detected in Aurora B and Bub1 
overexpression models, although the tumour incidence was higher in the Aurora B overexpression model 
(93%) compared to Bub1 overexpressing mice (62-71%). In both models, the resulting tumours present 
similar aneuploid levels (12% and 15% in Bub1 and Aurora B splenic lymphomas). Our data are consistent 
with the idea of Ricke RM and colleagues that the tumourigenesis and aneuploidization they found could 
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be due to Aurora B hyperactivation (Ricke et al., 2011). Indeed, we have demonstrated that increased 
rates of aneuploidy can enhance spontaneous tumourigenesis during ageing, although tumourigenesis 
was a late event that did not occur in all tissues. 
 
3. Aurora B role in modulating p53 activity 
 
We were initially surprised by the fact that in Aurora B overexpressing mice, spleen tumours were 
much more frequent than epithelial tumours, such as lung or liver cancers commonly found in other CIN 
models (Kumari et al., 2014; Schvartzman et al., 2011) and the levels of aneuploidy found in our tumours 
were not as higher as in other mitotic models (Schvartzman et al., 2011; Ricke et al., 2011), which led us 
think that another mechanism was taking place.  
We reported previously that p53 is induced in Aurora B null embryos (Fernández-Miranda et al., 
2011) in agreement with the proposal that Aurora B-dependent phosphorylation of p53 may result in the 
increased degradation of this transcription factor (Gully et al., 2012). Inactivation of Aurora B also results 
in increased p53 activity and the subsequent induction of the cell cycle inhibitor p21Cip1 in different cell 
types (Gully et al., 2012; Wu et al., 2011). Indeed, our group has recently described that inactivation of 
Aurora B leads to increased transcription of p21Cip1(Trakala et al., 2013).  
It is known that p53 maintains genomic stability in mice largely by p21 induction (Barboza et al., 
2006). Indeed, Aurora B deficiency leads to an enhanced expression of p21Cip1 resulting in aberrant Cdk 
activity and cell cycle progression (Lens et al., 2010; Trakala et al., 2013). Furthermore, it is known that 
p53 deficiency leads to cell cycle deregulation and aneuploidy (Negrini et al., 2010) and accelerates CIN 
and tumour formation in different mouse models by facilitating the propagation of genetically defective 
cells as a result of checkpoint loss. In addition, a correlation between abnormal p53 levels and aneuploidy 
has been described in human tumours (Thompson and Compton, 2010). 
Precisely, pharmacologic inhibition of Aurora B in cancer cells, increased p53 protein level and its 
target genes thus leading to an inhibition of tumour growth (Li et al., 2013). On the contrary, p53 deficiency 
in vitro leads to cell cycle deregulation and aneuploidy (Negrini et al., 2010). However, the relevance of 
this interaction in vivo has not been tested. Similar networks have been described for Aurora A and p53 
(Chiang, 2012; Hsueh et al., 2013; Katayama and Sen, 2011; Wu et al., 2012). All of these data led us to 
think that the tumourigenesis observed in the Aurora B overexpressing mice may be a consequence of the 
possible role of Aurora B in modulating p53 activity in vivo. Indeed, it has been hypothesized that 
conversion of diploid progenitor cells into cells that are aneuploid takes two steps. First, reduction in 
chromosome segregation fidelity occurs and second, acquisition of tolerance for a non-diploid genome 
that can arise through inactivation of the p53 pathway (Thompson and Compton, 2010).  
In this study we found that overexpressed Aurora B induces mitotic defects that lead to 
aneuploidy and this generates tumour induction and p21Cip1 downregulation (Figures 32 and 34). Some 
studies argued that p53 deficiency alone is insufficient to generate aneuploidy and that only when 
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combining p53 deficiency with elevated chromosome missegregation rates, p53 generates tolerance for 
the propagation of aneuploid cells (Thompson and Compton, 2010). Our data fit well with the observation 
that many tumour cells exhibit both aneuploidy and defects in the p53 pathway (Campomenosi et al., 
1998) (Tomasini et al., 2008); (Schvartzman et al., 2011), however, we do not know whether this 
permissive background is a pre-requisite for the development of aneuploidy or it is developed as an 
adaptation to overcome it. Likely, these two factors may contribute to tumour formation in specific cell 
types (Duesberg et al., 1998) (Duesberg et al., 1999) (Holland and Cleveland, 2009). Moreover, mutations 
in tumour suppressor genes tend to occur in the late stages of tumour formation, and such tumours are in 
the majority of cases aneuploid (Auer et al., 1994) (Baker et al., 1990). Most probably, loss of p21Cip1 
eliminates the checkpoints that arrest polyploidy and aneuploid cells generated upon Aurora B 
overexpression so that the resulting cells are prone to become transformed. 
 Furthermore, we observed that Aurora B overexpressed-tumours presented a downregulation of 
p21 and p53 levels which suggests that Aurora B is indeed a critical regulator of p53 in vivo and that 
overexpression of this kinase in cancer may lead to deficient p53 function and reduced levels of p53 
targets such as the cell cycle inhibitor p21Cip1. These results are also in agreement with an inverse 
correlation between Aurora B and p21Cip1 mRNA levels in human B-ALL (Fig. 41). It is likely that 
aneuploidy and defective p53 expression contribute to tumour formation as a result of Aurora B 
hyperactivation (Figure 48).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 48. Global scheme of the the outcomes obtained from Aurora B depletion and overexpression models. Aurora B 
depletion in vivo leads to a premature ageing phenotype as a consequence of impaired cell proliferation and aneuploidy. On the 
other hand, the overexpression of Aurora B induces mainly aneuploidy and a defective DNA damage response and as a 
consequence, tumourigenesis is induced. 
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4. Aurora B and metabolism 
 
Aurora kinases are widely known due to its role in mitosis. However, do Aurora kinases have a role 
outside mitosis? While the main focus on Aurora-A has been its actions in mitosis or cancer, it is 
increasingly apparent that the protein has important functions in non-mitotic cells, generally in cases in 
which the protein is overexpressed. Indeed, it has been reported its role in microtubule dynamics, cell 
migration, and polarity (neurite extension) (Lorenzo et al., 2009) (Yamada et al., 2010) (Mori et al., 2009), 
induction of disassembly of cilia (Pugacheva et al., 2007), and regulation of intracellular calcium signaling 
(Plotnikova et al., 2011). Aurora B is a major histone H3 kinase that mediates gene silencing 
epigenetically during cell differentiation, independently of the cell cycle (Sabbattini et al., 2007). Aurora B 
exerts this function by deposition of the double epigenetic modification H3K9me3/S10ph at silent genes in 
differentiated mesenchymal stem cells which promotes HP1 β displacement from chromatin (Sabbattini et 
al., 2014). Furthermore, several evidences have recently suggested a role for Aurora B in G1-S transition 
as revealed by acute elimination of the protein in G0 cells probably by regulating the mTOR pathway 
and/or the levels of the p53 effector p21Cip1 (Suzuki et al., 2000; Trakala et al., 2013). Moreover, some 
years ago a study of Tárdaguila and collaborators described a role for Aurora B in the regulation of 
transcription initiation of thyroid receptor (T3)- responsive genes (Tardáguila et al., 2011). All these results 
indicated that Aurora B could have a role outside the mitotic field. 
The surprising metabolic phenotype observed in Aurora B overexpressing mice led us to think 
that Aurora B has non-mitotic functions by regulating different targets. Ample evidence has shown that the 
metabolic alterations are critical for the growth, proliferation and survival of tumour cells. Our results 
suggests that there is a tendency in the Aurora B overexpressing mice to consume less energy and to 
present less metabolic flexibility (due to a higher and flatter RQ value than wild type mice). Both 
parameters explain our macroscopic observations in terms of higher weight and steatosis and also 
indicates that Aurora B overexpressing mice consume less fat and more glucose than wild-type mice, in 
concordance with the fat storage found in several tissues. Moreover, transgenic mice eat slightly more and 
their activity is a little higher than in wild type. Since after 1.5 months of Aurora B overexpression we can 
see tendencies but not significative differences, the analysis of the Aurora B overexpressing mice at later 
doxycycline period would be crucial in order to decipher the metabolic outcome. These are preliminary 
results that will be further completed by analyzing whether a food intake defect exits in the transgenic mice 
versus the control mice and if so, we could study possible hypothalamus defects testing the main 
hypothalamic peptides. It would be of interest to check the levels of metabolites in serum and to analyse 
the levels of Uncoupling protein 1 (UCP1) in BAT of wild-type and inducible Aurora B mice and also to 
analyse in these animals the possible transcriptional differences in fat or thyroid. 
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5. Aurora C and pluripotency 
 
While Aurora A and B are widely expressed in dividing cells, Aurora C pattern is restricted to 
spermatogenesis and oocyte fertilization. Aurora C deficiency results in viable mice with subfertility defects 
such as heterogeneous chromatin condensation, loose acrosomes and blunted sperm heads (Kimmins et 
al., 2007a). Interestingly, Aurora C displays frameshift mutations in infertile patients with abnormal 
spermatozoa characterized by large heads and increased chromosomal content (Dieterich et al., 2007a), 
suggesting a critical role in mammalian spermatogenesis. Additional loss-of-function studies of Aurora C in 
oocytes suggest a critical role for this protein in meiosis (Sharif et al., 2010; Yang et al., 2010). It is 
important to note that Aurora C is highly expressed in oocytes and during the first embryo divisions to 
reach a minimum expression during the blastocyst stage (Hamatani et al., 2004). There is no Aurora C 
expression in blastocysts, implanted embryos or 3T3 fibroblasts. Why germ cells express Aurora C is 
unknown. On the other hand, it has been hypothesized that this protein may act as a CPC component 
(Sasai et al., 2004; Slattery et al., 2008; Yan et al., 2005). However, its relevance in CPC function and 
mitosis has not been fully elucidated given the reduced endogenous expression levels in cultured cell 
lines.  
Since Aurora C, the unknown member of the family, is very close to Aurora B one would expect 
that the overexpression of Aurora C could have the same consequences as the overexpression of Aurora 
B, however this is not the case in terms of stemness induction. Based on sequence and functional 
analyses Aurora B and C are very similar, however why germ cells express Aurora C is unclear. Could 
they have different regulatory functions? Previous data from our laboratory indicate that Aurora B null pre-
implantation embryos developed normally and were positively stained for phospho-histone 3, what 
suggested that Aurora B could be dispensable due to the presence of Aurora C. Aurora C was 
demonstrated to be responsible of these early cell divisions; whereas once the blastocyst is formed this 
kinase is replaced by Aurora B (except germ cells; Fernández-Miranda et al., 2011) (Figure 44). These 
data were confirmed by a study in which it was observed that the posttranscriptional regulation of Aurkc 
mRNA and the greater stability of the protein ensured enough kinase activity, despite loss of Aurora B, to 
support early embryonic cell divisions (Schindler et al., 2012). Moreover, Sabbattini P. and collaborators 
(Sabbattini et al., 2007) have previously identified a new role for Aurora B in epigenetically marking silent 
chromatin during cell differentiation, which made us think of an opposite role of both kinases in stemness 
function. 
In this work, we verified that Aurora C is expressed in ES cells and iPCs. In addition, the ability of 
Aurora C to increase the efficiency of reprogramming suggests for the first time the relevance of this 
protein in pluripotency induction. Pluripotency requires activation of specific gene expression programs 
and long-term silencing of genes that specify cell fates. Epigenetic modifications of the core histones form 
complex combinations on nucleosomes that are believed to reinforce activating and silencing effects of  
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transcription factors and participate in the maintenance of cellular memory of transcription states 
(Jenuwein and Allis, 2001; Turner, 2002). Since we observed an upregulation of epigenetic marks only 
when overexpressing Aurora C, we strongly believe that one of the different aspects between these two 
proteins is their comparative ability to induce epigenetic changes during reprogramming. So that the role 
of Aurora C is because of its intrinsic function and not because of their differential pattern of expression to 
that of Aurora B. Aurora C possibly has a new role in stemness maintaining by acting as a regulator of the 
epigenetic status of undifferentiated cells. 
These preliminary data supporting the role of Aurora C in pluripotency, along the relevance of 
Aurora C during meiosis (Dieterich et al., 2007a; Sharif et al., 2010; Yang et al., 2010) and in early cell 
divisions indicate that Aurora C display critical roles in germ cells and during early embryo development. 
We are planning to investigate how Aurora C mediates these changes by checking Aurora C promoter and 
by performing a genome-wide analysis of the putative binding of Aurora B and Aurora C to DNA in order to 
find the in vivo binding sites of both kinases to chromatin and to identify functional elements of the 
genome. 
  
6. Concluding remarks: Therapeutic implication of the use of Aurora B/C inhibitors 
 
The three members of the Aurora kinase family are overexpressed in several types of cancer 
(Giet et al., 2005; Sorrentino et al., 2005; Tanaka et al., 1999; Zekri et al., 2012; Zhou et al., 1998). Since 
this discovery, Aurora kinases are considered as important cancer targets (Domenech and Malumbres, 
2013; Lens et al., 2010) (Keen and Taylor, 2004) (Pérez de Castro et al., 2008). Indeed, several Aurora 
inhibitors have been developed during the last decade and most pre-clinical studies showed the potent 
antiproliferative defects of these compounds, such as Danusertib or AT9283 (Malumbres and Perez de 
Castro, 2014). Whereas initial efforts were focused on Aurora A, recent data suggest that Aurora B is a 
relevant therapeutic target for cancer treatment (Girdler et al., 2006; Girdler et al., 2008). Aurora B 
inhibitors are antitumoural agents that are at the moment in clinical trials I, II and III, among them, 
BI811283, AZD1152, GSK1070916 (Malumbres and Perez de Castro, 2014). Because many of the 
inhibitors can act in a similar manner against the three Aurora members and also against another kinases, 
it is important to discriminate the specific effects of the inhibition of Aurora B associated with the use of 
these inhibitors.  
Moreover, several phase I and II trials have been initiated to test the effect of Aurora inhibitors in 
combination with other drugs already approved for cancer treatment. Given the essential role of Aurora B 
in mitosis, its inhibition could in principle impair the proliferation of any tumour. This makes Aurora B 
inhibitors potential universal drugs for the treatment of oncologic disorders. The use of Aurora B inhibitors 
have shown promising results during the last years, however, their inclusion in routine anti-tumour 
therapies is still far to be achieved. Additional discoveries on the function of Aurora B need to be 
addressed to improve the efficacy of Aurora B inhibition for the treatment of cancer diseases. 
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Our findings indicate that Aurora B overexpression can lead per se to cancer development. This 
phenotype is likely produced by a combination of chromosomal instability induction and p21Cip1 down-
regulation during tumour development. Some Aurora B inhibitors such as Barasertib or AZD1152 induce 
apoptosis and are at the moment in clinical trials I/II (Yamauchi et al., 2013) (Baldini et al., 2013; 
Malumbres and Pérez de Castro, 2014), which is in concordance with the observed induction of Caspase-
3 positive cells in Aurora B depleted mice. One of the most interesting uses of Aurora B inhibitors is their 
ability to potentiate the responses induce by other agents. The newly discovered roles of Aurora B in 
aneuploidy and differentiation (this work), offer new possibilities to explore further combinations. DNA 
repair inhibitors or agents that selectively kill aneuploid cells can be interesting candidates for combination 
therapies. Different screenings must be considered to increase the differentiation and apoptotic phenotype 
induced by these inhibitors. 
The cellular stress that comes from chromosome imbalances, make aneuploid cells more 
sensitive to specific compounds, which can be used as a cancer strategy (Torres et al., 2008). Finding 
ways to inhibit it or even hyper-induce it, could have significant implications for anticancer therapies. 
Furthermore, treatment of cells with Aurora B inhibitors induces p53-dependent apoptosis in human 
leukaemia cells (Ikezoe et al., 2010), representing a major opportunity for anti-cancer drugs. 
Different markers have been used to monitor the efficacy of Aurora inhibitors, including mitotic 
index, spindle bipolarity and chromosome alignment (Chakravarty, 2011), nuclear volume  (Perez de 
Castro, 2013) or the percentage of aligned spindles (Palani, 2013). High proliferative rates have also been 
associated with tumours that better respond to Aurora B inhibitors, since proliferation requires Aurora B 
activity. In this sense, Aurora B could be used as a biomarker to test the proliferation status of tumours 
(Mendiola et al., 2009). The crosstalk between Aurora B and p53 (Wu et al., 2011) makes this protein a 
potential marker for a more potent effect of Aurora B inhibitors. As Aurora B inhibits p53 (Gully et al., 
2012), it can be postulated that a funcitonal p53 pathway could be reactivated upon Aurora B inhibition 
and therefore sensitize cells to this treament. p53 could be studied to confirm its utility as a biomarker for 
Aurora B inhibitors efficacy. Furthermore, genomic sequencing, transcriptomics or the analysis of the 
metabolome should be used to identify new biomarkers. 
This finding adds to a wide number of studies showing that deregulation of a single gene 
implicated in the mitotic machinery is sufficient to contribute to tumour initiation. Understanding the role of 
such an important mitotic kinase as Aurora B is crucial for deciphering disease pathogenesis and may also 
lead to new avenues for treating human cancers.As a whole, this study sheds light on the mechanisms by 
which Aurora B gain of expression induces in vivo tumourigenesis and chromosomal instability whereas its 
complete depletion impairs cell proliferation, a feature that has been critical for their consideration as 
putative cancer target. 
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Our data is of special relevance in tumourigenesis because it implies that Aurora B inhibition 
could sensitize tumours to anticancer compounds that work better against cancer cells with a p53 null 
background. Aurora inhibitors could possibly have an effect in restoring p53 activity at least in some 
specific tumours, so that it could be used as a prognostic biomarker for tumour progression and patient 
survival. 
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Conclusions 
 
1. Depletion of Aurora B in vivo impairs cell proliferation due to the generation of 
polyploid/aneuploid cells accompanied by an induction of the cell cycle regulator p53 and 
its main target p21Cip1. This results in defective tissue regeneration that leads to a 
premature ageing phenotype. 
 
2. Overexpression of Aurora B in vitro does not affect the other CPC components but 
induces increased loading of the mitotic checkpoint protein BubR1, chromosome 
segregation defects, and aneuploidy. 
 
3. Long-term overexpression of Aurora B impairs the DNA damage response and represses 
the cell cycle inhibitor p21Cip1 in vitro and in vivo. 
 
4.  Aurora B overexpressing mice are tumor prone, they mainly present follicular B cell type 
lymphomas and they present higher aneuploid levels than control mice. 
 
5. Overexpression of Aurora B causes metabolic defects in adult mammals, mainly white 
adipose tissue (WAT) inside the brown adipose tissue (BAT), liver steatosis and adipose 
hyperplasia.  
 
6. Aurora C overexpression enhances the number of stem cells colonies during the 
reprogramming process and upregulates several active epigenetic marks, suggesting a 
specific role for this kinase in pluripotent cells. 
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Conclusiones 
 
1. La ausencia de Aurora B in vivo impide una correcta proliferación celular, produciendóse 
como consecuencia poliploidías/aneuploidías acompañadas de una inducción del 
regulador del ciclo celular p53 y su principal diana, p21Cip1. Como consecuencia se 
produce una regeneración deficiente de los tejidos que da lugar un fenotipo de 
envejecimiento prematuro. 
 
2.  La sobre-expresión de Aurora B in vitro no afecta a otros components del CPC pero 
induce un aumento en los niveles de la proteína de control mitótico BubR1, defectos en 
la segregación cromosómica y aneuploidía. 
.  
3. La sobre-expresión a largo plazo de Aurora B disminuye la respuesta al daño al DNA y 
reduce la expresión del inhibidor del ciclo celular p21Cip1 in vitro e in vivo.  
 
4.  Los ratones que sobre-expresan Aurora B presentan una mayor incidencia de tumores, 
principalmente linfomas de tipo folicular los cuales se caracterizan por unos niveles altos 
de aneuploidía. 
 
5.  La sobre-expresión de Aurora B produce defectos metabólicos en ratones adultos, 
principalmente presencia de tejido adiposo blanco en el tejido adiposo marrón, 
esteatosis en hígado e hiperplasia de adipocitos.   
 
6.  La sobre-expresión de Aurora C provoca un incremento en el número de colonias 
pluripotentes durante la reprogramación celular y una potenciación en marcas 
epigenéticas de activación de cromatina, sugiriendo que Aurora C puede tener un papel 
especifico en la formación de células pluripotentes. 
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